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Abstract: Glioblastoma is a malignant grade IV glioma with a poor prognosis in humans. 
New therapeutics are desperately required. The nitrone OKN-007 (2,4-
disulfophenyl-PBN) has demonstrated effective anti-glioma properties in several 
rodent models and is currently being used as a clinical investigational drug for 
recurrent gliomas. In this study, we assessed the efficacy of OKN-007 in two 
adult (rat F98 and mouse GL261) and one novel pediatric (IC-3752GBM in nude 
mice) high grade glioma model. OKN-007 significantly reduced the percent 
necrosis (p<0.01) and tumor cell proliferation (p<0.05) in treated F98-tumor 
bearing rats compared to the untreated group. Based on molecular magnetic 
resonance imaging (MRI) results, OKN-007 was also found to significantly 
decrease (p<0.05) free radicals levels in treated F98 rats compared to the 
untreated group. We also assessed VEGFR-2 (vascular endothelial growth factor 
receptor 2) levels in untreated and OKN-007-treated GL261 mouse gliomas using 
molecular MRI. OKN-007 decreased significantly the levels of VEGFR-2 
(p<0.05) in GL261 gliomas compared to the untreated group. Furthermore, OKN-
007 was also able to decrease significantly the tumor volumes (p<0.01) and 
increase survival (p< 0.001) in GL261 treated mice. For the pediatric glioma 
study, MRI results showed that OKN-007 significantly decreased tumor volumes 
(p<0.05), increased diffusion (p<0.01) and perfusion rates (p<0.05) in a 
responsive cohort of IC-3752GBM treated animals. In addition, OKN-007 
significantly increased animal survival (p<0.05), decreased tumor cell 
proliferation (p<0.05) and microvessel density (p<0.05) in responsive IC-
3752GBM treated mice. Furthermore, the nitrone was also able to significantly 
decrease the immunoexpression of SULF2 (p<0.05) and PDGFRα (platelet-
derived growth factor receptor-α) (p<0.05), and significantly increase the 
expression of decorin (p<0.05) in responsive IC-3752GBM pGBM tumor bearing 
mice. Taken together, our findings showed that OKN-007 mediated multiple 
effects in different rodent glioma models, indicating that the efficacy associated 
with OKN-007 is a result of anti-proliferative, free radical scavenging, and anti-
angiogenic properties. Furthermore, OKN-007 might be also an effective anti-
cancer agent for some patients with pediatric gliomas, possibly by inhibiting the 
PDGFRα pathway, and could be considered as an additional therapy for pediatric 
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OKN-007 decreases tumor necrosis and tumor cell proliferation and increases apoptosis 
in a pre-clinical F98 rat glioma model 
 
1.1 INTRODUCTION 
Gliomas are primary brain tumors that represent 30% of all central nervous system tumors and 
80% of all malignant brain tumors [1-3]. Gliomas are classified into low grade (World Health 
Organization (WHO) grades I–II) and high grade (WHO grades III–IV) based on five main 
features: cytological atypia, anaplasia, mitotic activity, microvascular proliferation, and necrosis 
[4]. Glioblastoma (GBM) is categorized as a grade IV glioma, and it is the most common 
malignant and most aggressive type of primary brain tumor in adults [5]. Most patients diagnosed 
with this tumor die within one year from the diagnosis, and only 5% survive more than 5 years 
despite aggressive therapies [1]. Advances in genetics and molecular biology of the tumor and 
tumor microenvironment have led to the development of novel therapies for GBMs; however, 
better therapeutic options are still needed to cure patients diagnosed with GBM or to dramatically 
improve survival times.  
The roles of different nitrones, such as the nitrone compound OKN-007 (Oklahoma Nitrone-007; 
disodium 4-[(tert-butyl-imino) methyl] benzene-1,3-disulfonate N-oxide or disufenton), as 
anticancer agents and their possible mechanisms of action in gliomas have been studied in
2 
 
detail [6]. OKN-007 is a small molecule that can traverse the blood–brain barrier and has anti-
inflammatory, antioxidant, and proapoptotic properties [6]. Our group has established that OKN-
007 is an effective anti-cancer agent in rodent pre-clinical models for adult GBMs [7-9], and it is 
currently undergoing clinical trial assessment as a new investigational drug in recurrent GBMs. In 
an orthotopic rat F98 glioma model and a human U87 xenograft model in athymic rats, OKN-007 
was found to significantly increase the survival of treated versus untreated rats. Morphological 
magnetic resonance imaging (MRI) showed that tumor volumes in both of these models were 
significantly decreased in treated compared with untreated animals [8]. Despite these findings, the 
mechanism(s) of action of OKN-007 are not fully understood, and our research aims at 
identifying how OKN-007 mediates effects, such as necrosis and cell proliferation, on various 
tumor regions. 
MRI is routinely used for the diagnosis, treatment planning, and assessment of response to 
therapy for patients with gliomas [9-21]. Proton magnetic resonance spectroscopy (
1
H-MRS), 
which has been used in research and clinical settings to measure metabolite levels in the brain, 
and diffusion-weighted imaging (DWI), which is used to characterize tumor growth and 
vasculature by measuring microscopic translational motion of water molecules within tissues, 
have been shown to be among the most valuable techniques that can provide a more complete 
evaluation of functional, cellular, and metabolic information about human GBMs [22]. 
Here, we report the effects of OKN-007 within the necrotic tumor core and non-necrotic tumor 
parenchyma in a F98 rat glioma model assessed by DWI and supported by
 1
H-MRS. The F98 rat 
glioma model was chosen as a suitable experimental model for this study because it has a 
characteristic infiltrative pattern of growth that resembles human GBM and is classified as an 
anaplastic malignant tumor. Supporting histological data for necrosis, immunohistochemistry for 





1.2.1 Glioma implantation 
The animal studies were conducted with approval from the Institutional Animal Care and Use 
Committees of the Oklahoma Medical Research Foundation and the University of Utah Health 
Sciences Center. The F98 rat glioma cell implantation model was prepared as described 
previously [8]. F98 cells (10
5
 in 10-µl volume) were intracerebrally implanted with a stereotaxic 
device (2 mm lateral and 2 mm anterior to the bregma at a 3-mm depth) in 24 Fischer 344 rats 
(male 200–250 gm). The animals were divided into two groups: OKN-007–treated (n = 12) and 
untreated (n = 12) groups. Both groups were stratified to ensure that tumor sizes were similar 
before initiation of treatment.  
 
1.2.2 OKN-007 treatment 
OKN-007 (Ryss Laboratories, Union City, CA) was administered to the rats in their drinking 
water at a concentration of 0.018% w/v. The treatment started at 15 days after glioma cell 
implantation, when the tumor volumes were between 10 and 15 mm
3
, and was administered 
continuously until the end of the study. Rats receiving normal drinking water were used as 
untreated controls. The amount of OKN-007 consumed by each rat, which were housed in 
separate cages, was determined by weighing water bottles each day. No significant deviation was 
observed in the volume of liquid uptake of compound in these rats. The average intake of OKN-












H-MRS values were obtained in untreated (n = 7) and OKN-007–treated (n = 8) animals bearing 
F98 gliomas as well as a group of 6 normal Fischer 344 rats. All MR imaging experiments were 
conducted on a Bruker Biospec 7.0 T (Bruker Biospin, Germany) using a 72-mm quadrature 
volume coil for signal transmission and a rat head surface coil for signal reception. Tumor 
morphology was observed on T2-weighted (T2W) images obtained with the application of the 
spin echo pulse sequence, rapid acquisition with relaxation enhancement (RARE) using a TR 
(repetition time) = 5000 ms, TE (echo time) = 63 ms, 20 transverse 1 mm-thick slices, and a field 
of view of 3.5 × 3.5 cm
2




H-MRS was acquired using a stimulated-echo acquisition mode (STEAM) sequence with a TE 
of 4.4 ms, a TM (mixing time) of 10 ms, a TR of 3000 ms, 256 averages, and a spectral width of 
4006 Hz. A nonsuppressed MR spectrum was acquired beforehand by applying eddy-current 
correction to maximize signal intensity and decrease the peak linewidth. Water was suppressed 
with a variable power radio frequency pulses and optimized relaxation delays (VAPOR) 
suppression scheme. For all cases, the peak width (full width at half maximum) of the water peak 
was less than 30 Hz following localized shimming, which was conducted by using first- and 
second-order adjustments in Fastmap. A cubic voxel with sides of 3.0 mm was positioned in 
either the tumor or the contralateral normal brain tissue, while maximizing the amount of tumor 
tissue present in the voxel at all times. 
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To analyze the MRS data, we used a Mathematica (version 6.0, Wolfram Research, Champaign, 
IL) notebook written by our group. The spectra were then scaled in ppm by calibrating on the 
water peak (4.78 ppm). The major brain metabolic peaks were identified as N-acetylaspartate 
(NAA) at 2.02 ppm, choline and choline-containing compounds (total Cho) at 3.22 ppm, creatine 
(Cr) and phosphocreatine (referred to as total Cr) at 3.02 ppm, and mobile lipids (absent in the 
normal brain tissue), which appeared sharply at 1.3 ppm for the methylene group, 0.9 ppm for the 
methyl group, and 5.3 ppm for the vinyl protons on unsaturated fatty acyl groups, in tumor tissue. 
The quantification of variations in metabolite levels were evaluated as peak length ratios: Cho/Cr, 
NAA/Cr, Lip5.3 (vinyl)/Cr, Lip1.3 (methylene)/Cr, and Lip0.9 (methyl)/Cr. 
 
1.2.3.1 DWI 
A coronal and axial multi-slice DWI sequence covering the entire tumor was performed using 
echo planar imaging–based pulse sequence with the following parameters: TR/TE = 3750/51.1 
ms, matrix size = 28 × 128, diffusion gradient duration = 4 ms, diffusion gradient separation = 14 
ms, and five b values ranging from 200 to 3000 s/mm
2
. Apparent diffusion coefficient (ADC) 
maps were generated for all the slices in which the tumor was observed. Uniform circular regions 
of interest (ROIs) (0.1 cm
2
) were drawn in the tumor parenchyma and tumor necrotic core in each 
slice of each animal from each group. The ADC of each ROI was recorded and the mean ADC 




/s) were obtained for each region of the tumor. The 
numbers of ROIs for the tumor parenchyma in the untreated group (n = 12) and OKN-007–treated 
(n = 12) groups were >1600. The numbers of ROIs for the tumor necrotic core in the untreated 
group and OKN-007–treated groups were >500.  
 
1.2.4 Quantification of tumor necrosis  
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Whole brains of one rat from the untreated group and one rat from the OKN-007–treated group 
were removed, preserved in 10% neutral buffered formalin, and processed under routine 
conditions. The paraffin-embedded brain tissues were completely sectioned in 4-μm slices in the 
axial plane to correspond to the plane of the MR images. Each tissue section was mounted on 
frosted glass slides and stained with hematoxylin and eosin (H&E). All histological slides from 
both animals were digitized using the Aperio ScanScope Image Analysis System (Aperio, Vista, 
CA) at the University of Oklahoma Health Sciences Center. Necrosis and whole tumor areas were 
measured in each histological slide using the Aperio ImageScope software. Percent tumor 
necrosis was calculated with the following formula: (total necrotic tumor area/total tumor area) × 
100. 
Percent tumor necrosis in untreated (n = 10) and OKN-007 (n = 8) treated animals was also 
calculated from T2W images. Tumor and necrotic volumes (mm
3
) were measured by drawing 
freehand ROIs to measure their areas and multiplied by the slice thickness and number of slices 
where the tumor and necrotic tumor core were observed. Percent tumor necrosis was calculated 
with the following formula: (total necrotic tumor volume/total tumor volume) × 100.  
 
1.2.5 Quantification of tumor cellularity 
Tumor cellularity was calculated in one representative H&E-stained slide for animals from each 
group (untreated and OKN-007–treated) using the Aperio ScanScope Image Analysis System. 
The number of tumor cells was counted in three 1-mm
2
 ROIs for each H&E-stained slide from 
each animal. Areas adjacent to or within necrotic or inflammatory regions were excluded while 
counting the tumor cellularity. The mean and standard deviation of the number of cells per mm
2
 





To characterize tumor cell proliferation and apoptosis in both untreated and OKN-007–treated 
groups, immunohistochemistry for Ki-67 antibody (1:100 dilution, rabbit polyclonal, clone PA5-
19462, Thermo Fisher Scientific, IL) and active/cleaved Caspase 3 (1:200 dilution, rabbit 
polyclonal, clone NB600-1235, Novus Biologicals, CO) was performed using an automated 
immunostainer (Leica, Bond-III, Leica, Buffalo Grove, IL).  
The Aperio ScanScope Image Analysis System was used to determine the KI-67 labeling index 
(Ki-67 LI) and apoptotic index (AI). The areas with the highest number of labeled nuclei were 
identified in each case. Ki-67 LI and AI were determined by counting 1000 cells and expressing 
this as the number of labeled cells per 1000 cells [23] for each animal from both untreated and 
OKN-007–treated groups. Labeled cells adjacent to or within necrotic areas were excluded while 
counting the Ki-67 LI and AI. The mean and standard deviation of Ki-67 LI and AI were 
determined for each group. 
 
1.2.7 Microarray 
RNA was isolated from the brain tissue and further purified using an RNeasy Mini Kit (Qiagen, 
Valencia, CA) and the RNA cleanup protocol provided. After purification, the RNA 
concentration was determined with a Nanodrop 2000c scanning spectrophotometer (Thermo 
Scientific, Wilmington, DE) and then qualitatively assessed for degradation using the ratio of 
28:18s rRNA obtained from a capillary gel electrophoresis system (Agilent 2100 Bionalalyzer, 
Agilent Technologies, Santa Clara, CA). 
The Illumina TotalPrep RNA Amplification Kit was used for labeling cRNA (Ambion, Austin, 
TX). Briefly, 200 ng of total RNA was primed with T7-oligo-dT and reverse transcribed; this was 
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followed by production of double-stranded cDNA with E coli DNA polymerase. cRNA was 
transcribed in vitro from the T7 promoter using a biotinylated ribonucleotide analog. cRNA was 
hybridized to HumanRef-8 v2 Expression BeadChips as specified by Illumina (San Diego, CA). 
BeadChips were washed and stained according to the Illumina protocol and scanned with an 
Illumina BeadArray Reader. 
Illumina BeadStudio software was used to quantitate the signal from BeadChips, and the 
MATLAB normalized values were imported into BRB ArrayTools (Biometric Research Branch, 
National Cancer Institute) where they were then log transformed. Genes that fell below the 50
th
 
percentile of gene variance were excluded from the results. We identified genes that were 
differentially expressed between any two classes by using a multivariate permutation test [24,25]. 
We used the multivariate permutation test to provide a median false discovery rate of 5% (90% 
confidence). The test statistics used were random variance t-statistics for each gene [26]. Genes 
that were differentially expressed (<5% false discovery rate) and had a ratio twofold or larger 
were used in further analyses. 
Pathways were explored by placing the data of genes that only passed our significance/ratio 




1.2.8 Statistical analysis 
Statistical analyses were performed using Graph Pad Prism 6 (GraphPad, San Diego, CA, USA). 
All p values < 0.05 were considered statistically significant. Peak area ratios [Cho/Cr, NAA/Cr, 
Lip1.3 (methylene)/Cr, Lip0.9 (methyl)/Cr, and Lip5.3 (vinyl protons)/Cr], ADC value, total 
percent necrosis, tumor cell density, Ki-67 LI, and AI were reported as the mean ± standard 
deviation. For statistical analysis, Student t-tests (independent-samples, two-tailed t-test) were 
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1.3.1 OKN-007 inhibited tumor necrosis in the F98 rat glioma model 
1
H-MRS values were obtained in normal Fischer 344 rats (n = 6) and in untreated (n = 7) and 
OKN-007–treated (n = 8) rats bearing F98 gliomas. Figure 1.1 shows that the Lip5.3/Cr (p < 
0.0001), Lip0.9/Cr (p = 0.0012), and Lip1.3/Cr (p = 0.0015) ratios were significantly lower in 
OKN-007–treated group than in the untreated F98 gliomas at the end phase of tumor progression. 
A total of 24 (untreated, n = 12; OKN-treated, n = 12) rat F98 gliomas were subjected to DWI. 
ADC maps (Fig. 1.2A,B) were generated from the images and used to determine the ADC value 
of the necrotic tumor core in each animal from each group. ADC values at the necrotic tumor core 
of the OKN-007–treated group were significantly lower than in the untreated group (p < 0.05) 
(Fig. 1.2C). 
Morphological TW2 images also were used to assess the percent necrosis tumor volume in both 
groups, which was significantly higher (p < 0.01) in the untreated group (20.08% ± 2.00, n = 10) 
than in the OKN-007–treated group (11.96% ± 1.80, n = 7) (Fig. 1.3). 
The percentage of tumor necrosis compared with the total tumor area on H&E-stained tumor 
sections was higher in the untreated group (23.44%, n = 1) compared with the OKN-007–treated 
group (10.32%, n = 1) (Fig. 1.4). 
Furthermore, a partial microarray pathway analysis of isolated RNA from untreated and OKN-
007–treated F98 gliomas shows downregulation of genes associated with calcium-channel 
10 
 
regulation due to OKN-007 (Fig. 1.5). The matrix Gla protein (MGP) and the microfibrillar-
associated protein 4 (MFAP4), which are directly associated with calcium-channel regulation, 
were both down-regulated by OKN-007. Two other genes linked to calcium-channel regulation 
were down-regulated by OKN-007: fibronectin type III domain-containing 1 gene, which is 
associated with G-protein βγ, and ADAM metallopeptidase, which is associated with the tumor 
necrosis factor (TNF). 
 
1.3.2 OKN-007 inhibited tumor cell proliferation in the F98 rat glioma model 
The Cho/Cr (p = 0.0004) ratio obtained in 
1
H-MRS data was significantly lower in the OKN-007–
treated group compared with untreated F98 gliomas at the end phase of tumor progression (Fig. 
1.1). 
The OKN-007–treated group showed significantly higher (p < 0.05) ADC values for the non-
necrotic tumor parenchyma in the treated group than for the untreated group (Fig. 1.2D). 
The tumor cell density (number of tumor cells/mm
2
) was evaluated on the H&E-stained tumor 
sections of both treatment groups. The OKN-007–treated group (7571 ± 251, n = 10) showed 
significantly lower (p < 0.001) cellularity compared with the untreated group (8442 ± 139, n = 
10) (Fig. 1.6).  
Tumor cell proliferation was also evaluated through the immunoexpression of the anti-Ki-67 
antibody. The Ki-67 LI was significantly lower (p < 0.05) in the OKN-007–treated group (53.25 
± 5.72, n = 6) than in the untreated group (71.73 ± 5.31, n = 7) (Fig. 1.7A–C). 
OKN-007 increased apoptosis in the F98 rat glioma model. The AI was significantly higher (p < 
0.01) in the OKN-007–treated group (27.09  2.25, n = 5) compared with the untreated group 




Figure 1.1.  Effects of OKN-007 in a F98 glioma model assessed by 
1
H MR spectroscopy. (A) 
Representative spectra from F98 gliomas depicting alterations in metabolite ratios from normal 
brain and OKN-007 treated and untreated (UT) glioma tissues. Spectra were obtained at the end-
tumor time points.  (B) Brain metabolite ratios measured by 
1
H-MRSI in normal rat brain (n = 6) 
and UT (n = 7) and OKN-treated (n = 8) F98 rat gliomas. The UT group showed significantly 
higher Cho/Cr (p<0.0001), NAA/Cr (p=0.0226), Lip5.3 (p<0.0001), Lip1.3 (p=0.0007), and 
Lip0.9 (p=0.0008) compared to the normal rat brain. The Cho/Cr (p=0.0004), NAA/Cr 
(p=0.0279), Lip5.3/Cr (p<0.0001), Lip0.9/Cr (p=0.0012), and Lip1.3/Cr (p=0.0015) ratios 
significantly decreased in OKN-007 treated group compared to UT F98 gliomas at the end phase 
of tumor progression. The OKN-007 treated group demonstrated significantly higher Lip5.3/Cr 
(p=0.0132), Lip1.3/Cr (p=0.0030), and Lip0.9/Cr (p=0.0114) ratios compared to the normal rat 
brain. There was no significant difference between the Cho/Cr (p=0.2436) and NAA/Cr 
(p=0.7281) ratios from the OKN-007 treated group and normal rat brain. Values are represented 
as means ± SD.  Asterisks indicate statistically significant difference (*p < 0.05, **p < 0.01, ***p 
< 0.001, ****p < 0.0001). n.s.: not statistically significant. Cho: choline, Cre: creatine, Lip5.3: 




Figure 1.2. Regional changes in apparent diffusion coefficients (ADCs) after OKN-007 
treatment of F98 gliomas. Representative ADC map for untreated (UT) (A) and OKN-007–
treated (B) F98 rat gliomas. Dashed line indicates the necrotic core (hyperintense region in 
tumor interior) and solid line indicates the non-necrotic tumor parenchyma (hypointense region 





, n=12, >500 ROIs) group were significantly lower than in 




, n=12, 529 ROIs). (D) The ADC values at the non-




, n=12, >1600 





, n=12, >1600 ROIs). In the box and whisker plots in C and D, the box extends from 
the 25
th
 to the 75
th
 percentile of ADC values, the line within the box is the median ADC value, 
and error bars are the minimum and maximum ADC values. Asterisks indicate statistically 







Figure 1.3. Representative T2W images for untreated (UT) (A) and OKN-007–treated (B) 
F98 rat gliomas. Dashed line indicates the necrotic core (hyperintense region in tumor interior) 
and solid line indicates the non-necrotic tumor parenchyma (hypointense region surrounding 
hyperintense necrotic core). (C) The percent necrosis tumor volume was significantly higher in 
the UT group (20.08±2.00, n=10) compared with the OKN-007 treated group (11.96±1.80, n=7) 
as measured on T2W images. Values are represented as means±SD. Asterisks indicate 





Figure 1.4. Representative histological (H&E) images from an untreated (UT) F98 glioma 
(A) and an OKN-007–treated F98 rat glioma (B). (C) The percent necrosis tumor volume as 
measured on H&E sections was higher in the UT group (23.44, n=1) than in the OKN-007–
treated group (10.32, n=1). Values are represented as means±SD. Slides in A and B were 







Figure 1.5. Microarray assessment of the effect of OKN-007 on calcium (Ca
2+
) channel 
regulation. Pathway analysis of isolated RNA from F98 gliomas that were untreated (n=5) 
compared with those that were OKN-007–treated (n=5) revealed down-regulation (depicted by 
a green color) in genes associated with calcium-channel regulation with a twofold difference 
and 5% false discovery rate. ADAMTS8: ADAM metallopeptidase with thrombospondin type 
1 motif, 8; FNDC1: fibronectin type III domain containing 1; MFAP4: microfibrillar-associated 
protein 4; MGP: matrix Gla protein; TNF: tumor necrosis factor; TNFSF9: tumor necrosis 




Figure 1.6. The tumor cell density (number of tumor cells/mm
2
) obtained from histological 
sections was higher in the untreated (UT) group (8442±139, n=10) than in the OKN-007–





 percentiles of tumor cell density, the line within the box is the median tumor cell density, 
and error bars are the minimum and maximum values. Asterisks indicate statistically significant 




Figure 1.7. Immunohistochemical nuclear staining of Ki-67 in an untreated (UT) (A) 
(×200) and OKN-007–treated (B) F98 rat glioma (×200). (C) The Ki-67 labeling index was 
significantly lower in the OKN-007–treated group (53.25±5.72, n=6) compared with the UT 
group (71.73±5.31, n=7). Immunohistochemical nuclear staining of cleaved caspase-3 in an UT 
(D) (×200) and OKN-007–treated (E) F98 rat glioma (×200). (F) The apoptotic index was 
significantly higher in the OKN-007 treated group (27.09±2.24, n=5) compared with the UT 
group (11.69±3.37, n=7). Asterisks indicate statistically significant difference (*p<0.05, 




The anti-cancer response to OKN-007 in F98 gliomas was previously reported by our group 
based on morphological (T2W) imaging, bioluminescence imaging, and immunohistochemistry 
assessments, in addition to survival data [8]. OKN-007 significantly decreased tumor volumes (p 
< 0.05), as measured by MRI, and increased survival (p < 0.001) in F98 glioma-bearing rats [8]. 
Assessment of treatment response using other MR parameters, such as 
1
H-MRS, DWI, and 
perfusion rates, was also performed by our group in C6 glioma models [7,27], but the use of a 
multi-parametric approach has not been previously reported for the rat F98 glioma model.  
1
H-MRS is a very useful method to obtain information on various tumor metabolites and to also 
assess treatment response. The principal metabolites that can be assessed by 
1
H-MRS in brain 
tumors include Cho (3.2 ppm), Cr (3.0 ppm), NAA (2.0 ppm), and lipids (Lip; 0.9–1.3 ppm) [28]. 
Cho is involved in the synthesis and degradation of cell membranes, levels of which may increase 
in conditions of cell proliferation, inflammation, or demyelination. Furthermore, a linear 
correlation has been demonstrated between Cho and the cell proliferation index for Ki-67 positive 
cells [29-31]. Cr, consisting of creatine and phosphocreatine, is a marker for brain energy 
metabolism, which involves the production of extra energy when normal cellular energy 
production does not meet the needed energy demand. NAA, which is generated by neurons, 
diffuses along axons and is degraded in oligodendrocytes [32-34]. As a normal neuronal marker, 
NAA is reduced during any neuronal or axonal damage or loss. Membrane lipids are usually non-
detectable by 
1
H MRS, because of their decreased mobility and strong dipolar couplings; 
however, in pathological conditions, the release of fatty acids from membranes and/or lipid 
droplets increases the concentration of free lipids that appears as sharp peaks at 1.3 ppm 
(methylene group, CH2) and 0.9 ppm (methyl group, CH3) [34]. These lipid signals originate from 
fatty acyl chains of triacylglycerides that form mobile lipid droplets in the cytoplasm of intact 
cancer cells [35,36] or in the necrotic core of tumors [37-40]. Additionally, mobile 
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polyunsaturated fatty acyl chain signals can be detected at 5.3–5.4 and 2.8 ppm and can be used 
to assess polyunsaturation of mobile lipids [36,41-43]. Intratumoral lipid droplets have been 
shown to correlate with drug resistance or therapy response [35]. Cytoplasmic accumulation of 
triacylglycerides in cancer cells and tumors has been attributed to diverse biological processes 
such as hypoxia, degeneration of mitochondria, differentiation, growth arrest [35,36], and 
apoptotic [44,45] and necrotic cell death [39,46-48]. 
Another useful magnetic resonance technique to assess tumor heterogeneity is DWI. DWI is 
routinely used to measure microscopic, random translational motion of water molecules within 
tissues. Any alterations in the tissue structure that disrupt the barriers of water diffusion, such as 
the breakdown of cell membranes or damage to fibers, would lead to changes in the diffusion 
properties within these regions. These diffusion characteristics can be quantified by estimating 
the ADC. DWI has been shown to be a very effective modality to characterize tumor growth and 
vasculature [7,49]. In tumors, ADC values can differentiate the cellular mechanisms involved in 
tumor development as well as responses to treatment such as cell proliferation, apoptosis, and/or 
necrosis [50]. Processes that degrade cellular integrity, such as necrosis caused by therapy or 
tumor growth, are thought to increase the ADC of tissue [51,52]. Conversely, since water 
molecules are more restricted in their movement within cells than in the extracellular space, high 
cell density is associated with a low ADC [53,54]. Studies have also shown the potential for ADC 
to be of diagnostic and prognostic value as a surrogate marker for assessment of therapeutic 
response in various cancers [54-64]. 
In this study, we attempted to understand the regional effect of OKN-007 in two different regions 
(the necrotic tumor core and the non-necrotic tumor parenchyma) in a F98 rat glioma model, 
considering the heterogeneous nature of the tumor and the multiple mechanisms of action effects 
mediated by OKN-007. We demonstrated that OKN-007 inhibited both tumor necrosis and cell 
proliferation in a F98 rat glioma model (Figure 1.8). The 
1
H-MRS data showed a statistically 
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significant decrease in the vinyl protons (5.3 ppm)/Cr, methylene (1.3 ppm)/Cr, and methyl (0.9 




Figure 1.8. Schematic summary of the different mechanisms of action of OKN-007 therapy 
in a F98 rat glioma model. All solid malignancies, at some point outpace their blood supply and 
become oxygen and nutrient deprived. This results in necrotic cell death at the tumor’s core and 
the release of pro-inflammatory mediators, leading to the tumor promotion. Tumor growth may 
also be stimulated in response to hypoxia-induced necrosis in the tumor’s core. OKN-007 inhibits 
tumor necrosis and cell proliferation and promotes the tumor cell apoptosis in F98 rat gliomas 
based on the 
1
H-MRSI, DWI, immunohistochemical, and microarray data analyses. HIF-1α: 




The role of mobile lipids in cancer has been the subject of many excellent reviews and articles 
[9,27,35,39,45,65-70]. In brain tumors, the elevation of the lipid levels usually correlates with 
necrosis [35,37,65,71], and lipids are considered as important biomarkers in the diagnosis and 
monitoring the effects of treatment response [65].  
Necrosis is a hallmark of GBMs [4,72], with some studies suggesting it is present in over 85% of 
cases [73-76]. It is caused by tumor hypoxia as a result of increased cell proliferation and mitotic 
activity, as well as insufficient tissue perfusion [72,77]. The pathway of necrosis in glioblastoma 
begins with acute cellular ATP depletion as a result of electron transport chain collapse and 
subsequent decreased oxidative phosphorylation [78]. This lack of ATP leads to a failure in the 
ATP-dependent ion channels and pumps, which initiates a massive cell volume increase through 
Na
+
 influx. The increased intracellular Na
+





ATPase, which further depletes cellular ATP stores [79]. This depletion leads to the opening of 
non-selective Ca
2+
 channels, resulting in elevated intracellular Ca
2+
 levels and activation of the 
Ca
2+
-ATPase with eventual mitochondrial depolarization [79]. In addition, with severe ATP 
depletion, ionic homeostasis is no longer maintained by the K
+
 efflux, leading to further Na
+
 and 
water influxes that precipitate cellular swelling and collapse. As the cell membrane ruptures, the 
contents of the cells are released into the extracellular space, which will lead to the presence of 
high lipid peaks that are detected in 
1
H-MRS. 
A number of studies have also demonstrated that the increase in mobile lipids is associated with 
the onset of drug-induced apoptosis [47,65]. Interestingly, the OKN-007–treated F98 gliomas 
demonstrated significantly higher Lip5.3/Cr (p = 0.0132), Lip1.3/Cr (p = 0.0030), and Lip0.9/Cr 
(p = 0.0114) ratios compared with the normal rat brain, which might be due to an increase in 
apoptosis observed in the OKN-007–treated animals. In our study, the AI was significantly higher 
in the OKN-007–treated group (27.09 ± 2.24, n = 5) compared with the untreated group (11.69 ± 
3.37, n = 7) (Fig. 1.7D-F). 
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These spectroscopic findings were also confirmed by DWI and histopathological data analyses. In 
our study, we effectively showed that ADC values at the necrotic tumor core of OKN-007–treated 
group were significantly lower than those in the untreated group (p < 0.05) (Fig. 1.2).  
The inhibitory effect of OKN-007 in the necrotic tumor core of F98 gliomas was also noted based 
on the T2W images from each treatment group (Fig. 1.3). The percent necrosis tumor volume was 
significantly lower (p < 0.01) in the OKN-007–treated group (11.96% ± 1.80, n = 7) compared 
with the untreated group (20.08% ± 2.00, n = 10).  
Necrosis volumes were also measured quantitatively from H&E-stained tumor sections, which is 
the gold-standard technique to evaluate tumor necrosis. The analysis was performed in H&E-
staining sections of the whole tumor from one representative animal from each treatment group. 
OKN-007 also decreased the percentage of tumor necrosis compared with the total tumor area on 
H&E-stained tumor sections in a treated F98 glioma rat (10.32, n = 1, 1118 H&E sections) 
compared with an untreated animal (23.44, n = 1, 1215 H&E sections) (Fig. 1.4).  The possible 
explanation for this observation could be that OKN-007 affects necrosis by down-regulating the 
genes associated with Ca
2+
 channels, thereby reducing the intracellular Ca
2+
 levels. The effect of 
OKN-007 on genes associated with Ca
2+
 channels was confirmed by our microarray results 
wherein OKN-007 was shown to down-regulate two genes, MGP and MFAP4, which are directly 
related to Ca
2+
 channels. MGP is down-regulated by a 3.16-fold change and MFAP4 is down-
regulated by a 2.16-fold change as a result of OKN-007 treatment (Fig. 1.5). In addition, a few 
other genes associated with Ca
2+ 
channels also seem to be down-regulated by OKN-007 as shown 





-related genes could also lead to reduced expression of genes for TNFα, which in turn 
down-regulates the NF-κβ pathway, thereby causing a decrease in necrosis. There was also down-
regulation of ADAMTS8, which is directly linked to TNF. 
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Furthermore, our study also demonstrated that OKN-007 inhibited tumor cell proliferation in the 
F98 rat glioma model. Previous studies have confirmed that the relative increase in choline in 
most high-grade gliomas is due to the increase in membrane synthesis and accelerated cell 
proliferation [80,81]. Total Cho, which resonates at 3.2 ppm, is a composite peak with 
contributions from choline, phosphocholine, and glycerophosphocholine. An increase in the total 
Cho resonance in tumors arises primarily from the synthesis and accumulation of 
phosphocholine, a metabolite produced by rapid uptake and phosphorylation of choline that is 
necessary for the downstream synthesis of phosphatidylcholine, a major membrane phospholipid 
constituting around 25% of mammalian cellular lipids [82,83]. Here, we demonstrated that OKN-
007 significantly decreased the Cho/Cr ratio (p = 0.0004) at the end phase of tumor progression 
(Fig. 1.1B), because of a decrease in the tumor cell proliferation, which was also confirmed by 
our DWI and histopathological results.  
Both intra- and extracellular spaces and their exchange contribute to the measured ADC. As 
cellular density increases, the added tortuosity to extracellular mobility paths reduces water 
mobility and, consequently, the ADC value [84]. Based on that observation, within a given tissue 
or cell type, ADC is useful as an indicator of the relative cellularity, such as in the evolution of 
tumor over time following therapy [85]. ADC is inversely proportional to cell density [86], and 
after an effective treatment the cellularity is reduced from apoptosis and necrosis, and the 
diffusivity increases [87]. A rise in ADC indicates a positive response to therapy. The observed 
increase in water ADC following therapy is directly related to the number of tumor cells killed 
and is thought to be due to the liberation of water into the extracellular space [85]. In our study, 





, n = 12, >1600 ROIs) were significantly higher (p < 0.05) than in the untreated 




, n = 12, >1600 ROIs) (Fig. 1.2D), reflecting less restricted 
diffusion consequent to a decrease in tumor cellularity in the OKN-007–treated F98 rat gliomas. 
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Tumor cell density (number of cells/mm
2
) and cell proliferation were also evaluated using H&E-
stained tumor sections and immunoexpression of the antibody anti-Ki-67, respectively. The 
OKN-007–treated group (7571 ± 251, n = 10) showed significantly lower cellularity (p < 0.01) 
compared with the untreated group (8442 ± 139, n = 10) (Fig. 1.6). Ki-67 LI was significantly 
lower (p < 0.05) in the OKN-007–treated group (53.25 ± 5.72, n = 6) compared with the untreated 
group (71.73 ± 5.31, n = 7) (Fig. 1.7A-C). 
Finally, our results also corroborated the results from other studies [31] that confirmed the 
positive correlation of the glioma Cho signal with cell density and an inverse linear correlation 
between glioma cell density and ADC values. 
 
1.5 CONCLUSION 
Our results indicate that OKN-007 mediates multiple effects on different (tumor necrotic core and 
non-necrotic tumor parenchyma) regions of the tumor in F98 gliomas that can be detected in vivo, 
indicating the efficacy of OKN-007 as an anti-cancer agent and its clinical potential. Our 
1
H-
MRS, DWI, immunohistochemical, and microarray data analyses showed that OKN-007 reduced 
necrosis and tumor cell proliferation. There was also an increase in apoptosis after OKN-007 
treatment that seemed to correlate with spectroscopic lipid alterations. Our results also indicated 
that both ADC and spectroscopic choline measures are related to glioma cell density in the F98 
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OKN-007 decreases free radicals levels in a preclinical F98 rat glioma model 
 
2.1 INTRODUCTION 
Free radicals, or more generally, reactive oxygen species (ROS) and reactive nitrogen species 
(RNS), or collectively RONS, are products of normal cellular metabolism [1], and are formed 
continuously in cells as a consequence of both enzymatic and nonenzymatic reactions [2]. In 
normal cells, there is a balance between free radical generation and antioxidant defense [3]. 
Oxidative damage can occur when this balance is unfavorable, affecting a wide range of 
molecular species including lipids, proteins, and nucleic acids [4]. Oxidative stress plays a major 
role in the development of chronic and degenerative diseases such as arthritis, aging, autoimmune 
disorders, cardiovascular, neurodegenerative diseases, and cancer [5]. 
By combining molecular magnetic resonance imaging (mMRI) and immuno-spin trapping (IST) 
technologies it is possible to monitor the levels of free radicals in vivo in real time [6]. Free 
radicals that are generated as a result of oxidative stress processes can be trapped by the spin-
trapping compound, 5,5-dimethyl-1-pyrroline N-oxide (DMPO), to form DMPO-R adducts (Fig 
2.1A), which can be further assessed by IST, a method that uses an antibody against   DMPO 
nitrone adducts. Therefore, the combined morphological image resolution of mMRI, the use of a 
gadolinium (Gd)-DTPA(diethylene triamine penta acetic acid)-albumin–based contrast agent 
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(Fig. 2.1B) for signal detection, and the specificity of antibodies for protein/lipid radicals (anti-
DMPO antibody, which binds to DMPO-protein/lipid adducts resulting from oxidative-stress-
induced formation of protein/lipid radicals), can used to detect in vivo oxidative stress–related 
processes (Fig. 2.1C) [6,7].  
This technique allows in vivo assessment of oxidation products, permitting the study of specific 
cause-consequence relationships from specific oxidative events. Recently our group reported for 
the first time regarding the use of this non-invasive in vivo method to detect and quantify free 
radicals levels in a mouse GL261 glioma model [6]. 
OKN-007 (2, 4-disulfophenyl-PBN; or disodium 4-[(tert-butyl-imino) methyl] benzene-1,3-
disulfonate N-oxide or disufenton; also previously known as NXY-059) is an anticancer drug [9-
11] and free radical spin-trapping agent that inhibits upregulation of  inducible nitric oxide 
synthase (iNOS),  decreases glutamate excitotoxicity [8], and has exhibited efficacy as a 
neuroprotectant. Scientific advancements in our understanding and detection of free radicals in 
biological systems, their importance in carcinogenesis, as well as the introduction of novel 
therapeutics such as OKN-007 that act by influencing free radicals [8] have dramatically 
enhanced our ability to assess the role of free radicals in both disease and normal physiology.  In 
this study, we combined mMRI with a Gd-DTPA-albumin-based contrast agent for signal 
detection with the specificity of an antibody for DMPO nitrone adducts (anti-DMPO probe), to 
detect in vivo free radicals levels in untreated and OKN-007 treated adult F98 rat glioma models. 
As a negative control, we used a non-specific IgG antibody covalently bound to the albumin-Gd-
DTPA-biotin construct. Verification of the presence of the probe in tumor tissues and in glioma 







Figure 2.1. Approach for combined in vivo mMRI and IST. (A) Free radicals that are 
generated as a result of oxidative stress processes can be trapped by the spin-trapping compound, 
5,5-dimethyl-1-pyrroline N-oxide (DMPO), to form DMPO-R adducts, which can be further 
assessed by immuno-spin trapping (IST), a method that uses an antibody against DMPO-nitrone 
adducts. (B) Schematic structure of anti-DMPO probe or non-specific IgG contrast agent. (C) 
Immuno-spin trapping of free radicals (R) with mMRI anti-DMPO probe. DMPO is injected i.p. 
to trap free radicals and generate nitrone-radical (R) adducts. Anti-DMPO is injected i.v. to target 
nitrone-R adducts, which can be visualized by mMRI. Modified from Biochimica et Biophysica 
Acta, 1832(12), Towner RA et al. (2013) [6]. Copyright (2013), with permission from Elsevier. 
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2.2 MATERIAL AND METHODS 
2.2.1 Glioma implantation 
The animal studies were conducted with approval from the Institutional Animal Care and Use 
Committee of the Oklahoma Medical Research Foundation. The F98 rat glioma cell implantation 
model was prepared as described in our previous work [9]. F98 cells (10
5
 in 10-µl volume) were 
intracerebrally implanted with a stereotaxic device (2 mm lateral and 2 mm anterior to the 
bregma, and at a 3 mm depth) in a total of 15 Fischer 344 rats (male 200–250 gm; Harlan 
Laboratories, Indianapolis, Indiana). The animals were divided into two groups: OKN-007 treated 
(n = 8) and untreated (UT) (n = 7) groups. Both groups were stratified to ensure that tumor sizes 
were similar before initiation of treatment. 
  
2.2.2 Syntheses of DMPO-specific MRI contrast agents 
To recognize the DMPO-radical adducts, we used an anti-mouse/rat monoclonal anti-DMPO 
antibody bound to a contrast agent. The macromolecular contrast material, biotin–BSA–Gd-
DTPA, was prepared using a modification of the method of Dafni et al. [12]. The biotin moiety in 
the contrast material was added to allow histological localization. Biotin– BSA–Gd-DTPA was 
synthesized as described in Towner et al. [13]. A solution of biotin–BSA–Gd-DTPA was added 
directly to the solution of antibody (anti-DMPO, 200 μg/mL) for conjugation through a sulfo-
NHS (N-succinimidyl-S-acetylthioacetate)–EDC (N-succinimidyl 3-(2-pyridyldithio)-propionate) 
link between albumin and antibody according to the protocol of Hermanson [14]. Sulfo-NHS was 
added to the solution of biotin–BSA–Gd-DTPA and EDC. This activated solution was added 
directly to the antibody (anti-DMPO, 200 μg/mL) for conjugation. The mixture was left to react 
for at least 2 h at 25 °C in the dark. The product was lyophilized and subsequently stored at 4 °C 
and reconstituted to the desired concentration for injections in phosphate buffer saline (PBS). The 
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final amount of the product, anti-DMPO–biotin–BSA–Gd-DTPA (anti-DMPO probe), that was 
injected into the rats is estimated to be 200 μg anti-DMPO Ab/injection and 100 mg biotin–BSA–
Gd-DTPA/injection. The estimated molecular weight of the anti-DMPO–biotin–BSA–Gd-DTPA 
probe is estimated to be 232 kDa. As negative control, normal rat-IgG conjugated to biotin–BSA–
Gd-DTPA (control IgG contrast agent) was synthesized by the same protocol to generate an 
isotype contrast agent.  
 
2.2.3 DMPO administration 
DMPO (ALX-430-090-G001, Enzo Life Sciences) was administered i.p. (100 mg diluted in 200 
μL of saline) 3× daily (every 6 h) for 3 days to trap free radicals during tumor formation. DMPO 
administration started when the tumor reached the volume of 70-80mm
3 
(Fig. 2.2).   
 
 
Figure 2.2 Schematic representation of the timeline for the experimental procedures used in 
this study. Top timeline represents tumor volumes (mm
3
), and the bottom timeline refers to the 
procedures performed (days). F98 rat glioma cell implantation was performed on day 0. 
Morphological (T2-weighted) MRI scans were started ten days after the F98 cell implantation and 
were performed every 2-3 days until the end of the study. OKN-007 treatment (anti-cancer 
therapy) was initiated when the tumor volumes were between 10 and 15 mm
3
.  DMPO 
administration (100 mg diluted in 200 μL of saline) (free radical trapping) was started when the 
tumor volumes were between 70 and 80 mm
3
. After DMPO treatment (at 24-28 days post F98 
cell implantation), injection of the anti-DMPO probe was done to detect the presence of free 




2.2.4 OKN-007 treatment 
OKN-007 (2, 4-disulfophenyl-N-tert-butyl nitrone, Ryss Laboratories, Union City, CA) was 
administered as an anticancer agent to the rats in their drinking water at a concentration of 
0.018% w/v. The treatment started at 13-15 days after glioma cell implantation, when the tumor 
volumes were between 10 and 15 mm
3
 (Fig. 2.2). The treatment was administered continuously 
until the end of the study. Rats receiving normal drinking water were used as UT controls. The 
amount of OKN-007 consumed by each rat, which were housed in separate cages, was 
determined by weighing water bottles each day. No significant deviation was observed in the 
volume of liquid uptake of compound in these rats. The average intake of OKN-007 was 
approximately 10 mg/kg/day. The F98 glioma bearing rats were divided in three different 
treatment groups: (1) OKN-007 treated animals + DMPO administration + anti-DMPO probe 
(n=5), (2) Untreated animals + DMPO administration + anti-DMPO probe (n=7), (3) Untreated 
animals + DMPO administration + IgG probe (n=4). The overall experimental scheme is shown 
in Fig. 2.2. 
 
2.2.5 MR Imaging 
All MR imaging experiments were conducted on a Bruker Biospec 7.0 T (Bruker Biospin, 
Germany) using a 72-mm quadrature volume coil for signal transmission and a rat head surface 
coil for signal reception. Tumor morphology was observed on T2-weighted images obtained with 
the application of the spin echo pulse sequence, RARE (Rapid acquisition with relaxation 
enhancement) using a TR (repetition time) = 5000 ms, TE (echo time) = 63 ms, 20 transverse 1 
mm-thick slices, a field of view of 3.5 × 3.5 cm
2
 with an in-plane resolution of 137 × 137 µm
2
. 
Starting ten days after the F98 tumor cells inoculation, each rat brain was imaged in vivo every 2-
3 days until the end of the study. Subsequently for the 3-day DMPO treatment, rats were injected 
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intravenously with anti-DMPO or non-specific-IgG antibodies tagged with a biotin–Gd-DTPA–
albumin-based contrast agent (200 μL/kg; 1 mg antibody/kg; 0.4 mmol Gd
+3
/kg). Rat brains were 
imaged at 0 (pre-contrast), 20, 40, 60, 120 and 180 min intervals post-probe or -contrast agent 
injection.  
T1-weighted images were obtained using a variable TR RARE (rapid acquisition relaxation-
enhanced) sequence (TR 200, 400, 800, 1200 and 1600 ms; TE 15 ms, FOV 2×2 cm2, matrix 
256×256, slice thickness 0.5 mm, 2 slices, and 2 steps per acquisition).  
 
2.2.6 Calculation of relative probe concentration 
Relative probe (contrast agent) concentrations were calculated to assess the levels of free radicals 
in each animal. A contrast difference image was created from the pre- and (120 minutes) 
postcontrast datasets for the slice of interest, by computing the difference in signal intensity 
between the post-contrast and the pre-contrast image on a pixel basis. On the difference image, 
three regions of interest (ROI) of equal size (0.02cm
2
) were drawn on the areas with the highest 
T1 relaxation in the tumor parenchyma and contralateral side of the brain of each animal after the 
probe (anti-DMPO or non-immune-IgG) injection at the TR 800 ms. The values obtained from 
the ROIs in the tumor region were normalized to the contralateral side. The T1 relaxation value of 
the specified ROIs was computed from all the pixels in the ROI by the following 
equation [15] (processed by ParaVision 4.0, Bruker): S(TR) = S0(1 − e
− TR / T1
), where TR is the 
repetition time, S0 is the signal intensity (integer machine units) at TR ≫ T1 and TE = 0, and T1 is 
the constant of the longitudinal relaxation time. An overlay of the contrast difference image and 
T1-weighted image was generated using the 3D Analysis Software for Life Sciences Amira® 





Whole brains from each rat in each treatment group were removed and embedded in Optimal 
Cutting Temperature (OCT) compound and frozen in liquid nitrogen. Frozen tissue blocks were 
sectioned at 10 μm, mounted on positive-charged slides, and air-dried for 30 minutes. Sections 
were fixed in acetone, and incubated with Horseradish Peroxidase (HRP) polymer kit (Biocare 
Medical), stained with DAB chromogen (Vector Labs), and then counterstained with hematoxylin 
(Vector Labs). 
 
2.2.8 Gold labeling immunoelectron microscopy 
Brain tissue was removed and cut to size of about 2cm and 3-5mm thick then fixed in 4% 
paraformaldehyde + 0.1% glutaraldehyde in 0.1M phosphate buffer (PB) for 1 hour at room 
temperature or at 4°C, and then washed thoroughly with PB (pH 7.3). Tissue was trimmed further 
to 1-2mm pieces. Osmication was omitted for labelling procedure. Dehydration was in an ethanol 
series (50%, 70%, 80%, at 15 min each). Tissue was placed in 2:1 LR White resin (Electron 
Microscopy Sciences, PA) to 70% ethanol for 1 hour to avoid tissue shrinkage, and then further 
infiltrated in 100% LR White for 1 hour, overnight, and then two changes for 30 minutes. Tissue 
was added to gelatin capsules and LR White polymerized at 50°C for 24 hours. Gold-silver 
sections were placed on nickel grids coated with formvar or colloidin.  Sections on grids were 
protein blocked in Aurion goat gold conjugate (Electron Microscopy Sciences, PA) for 30 
minutes, washed in PBS-0.2% bovine serum albumin 3x for 5 minutes at pH 7.4 (Electron 
Microscopy Sciences, PA). Aurion ultra small gold conjugate – goat anti-Biotin (Electron 
Microscopy Sciences, PA) in PBS-0.2% BSA-c was applied at 1:100 for overnight at 4°C or for 4 
hours at room temperature. Grids were washed in PBS-0.2% BSA-c (pH 7.4), 6x for 5minutes; in 
PBS, 3x for 5 minutes; in distilled water 5x for 2 minutes. Silver enhancement was done by 
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placing grids on a droplet of Aurion R-Gent SE-EM enhancement mixture (Electron Microscopy 
Sciences, PA) for 90 minutes, then washed in distilled water. Controls involved sections with no 
secondary antibody (anti-Biotin) and no silver enhancement. Sections were stained with uranyl 
acetate for 15 minutes followed by lead citrate for 3 minutes. Sections were viewed with a Zeiss 
T109 electron microscope with Gatan digital micrograph software operated at 80kV. 
 
2.2.9 Statistical analysis 
Statistical differences between the probe-administered and control groups were analyzed with an 
unpaired, two-tailed Student t test using commercially available software (InStat; GraphPad 




Representative examples of images obtained in F98 glioma-bearing rats are shown in Fig. 2.3.  
Pre- and post DMPO probe contrast images are shown in Figs. 2.3A and B, respectively. A T2-
weighted morphological image depicts the tumor location (outlined region in Fig. 2.3C). A 
difference image illustrating increased anti-DMPO probe accumulation is shown in Fig. 2.3D, 
along with representative ROIs in the tumor and contralateral (normal) brain regions.  
There were differences in the levels of free radicals detected in the different treatment groups. 
OKN-007 was found to significantly decrease (p = 0.0411) the levels of free radicals detected in 
the treated group compared to the untreated animals who were both administered the anti-DMPO 
probe. There was no significant difference in the level of free radicals detected between the OKN-
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007 treated group and the group that received the IgG probe (negative control group) (Fig 2.4A-
D).  
The difference between the amounts of anti-DMPO probe in untreated and OKN-007 treated F98 
rat gliomas was confirmed by using a streptavidin horseradish peroxidase (HRP) detection system 
(Fig. 2.5), whereby the streptavidin-HRP bound to the biotin moiety of the anti-DMPO probe 
(Fig. 2.1B) in excised tumor tissues . The amount of anti-DMPO probe was elevated in the UT 
F98 glioma rats administered with the anti-DMPO probe (Fig 2.5A), but not the ones 
administered with OKN-007 (Fig 2.5B) and/or the UT glioma-bearing rats given the non-specific 
IgG contrast agent (Fig 2.5C).  
Ex vivo immunoelectron microscopy of F98 rat glioma tissues after administration of gold-labeled 
anti-biotin was performed to determine the sub-cellular localization of the anti-DMPO probe (Fig 
2.6). The gold-labeled anti-biotin was found to be distributed within the plasma membrane, as 
well as the nuclei of the F98 tumor cells in rats administered the anti-DMPO in vivo (Fig 2.6A). 
In comparison the control tumor cells (previously administered the non-specific IgG contrast 








Figure 2.3. Morphological MR images obtained before and 2 hrs after injection of anti-
DMPO probe (contrast agent) in a F98 rat glioma moldel. (A)  Representative T1-weighted 
image before injection of the anti-DMPO probe. (B) Representative T1-weighted image 2 hours 
after injection of the anti-DMPO probe. (C) Representative T2-weighted image of F98 rat glioma. 
(D) Representative difference image, which is the subtraction between the T1 images of pre- and 
2 hrs after injection of the contrast agent (A-B). The dark regions in the tumor depict areas of 
increased uptake of the anti-DMPO probe. Representative ROIs in the tumor and contralateral 
side of the brain are illustrated as circles in each region. The tumor is delineated  by a dotted line 




Figure 2.4. mMRI detection of free radical adducts in a F98 rat glioma model. 
Representative MR images from: (A) Untreated + anti-DMPO probe, (B) OKN-treatment + anti-
DMPO probe, (C) Untreated + IgG probe, F98 rat gliomas. (A-Ci) T2-weighted images of F98 
glioma. (A-Cii) T2-weighted images overlayed with a difference T1-weighted image (red), which 
was the subtraction between the 2 hr post-contrast and the pre-contrast images after injection of 
either the anti-DMPO probe or the IgG contrast agent. Overlays of the contrast difference images 
and the T2-weighet images were generated using the 3D Analysis Software for Life Sciences 
Amira®. (D) OKN-007 was found to significantly decrease (p = 0.0411) (1.407 ± 0.1548, n=5) 
the levels of free radicals in the treated group compared to the untreated animals (5.131 ± 1.437, 
n=7), which both received the anti-DMPO probe. There was no significant difference between the 
OKN-007 treated group and the untreated animals that received the IgG contrast (negative control 
group). Values are represented as means ± SD.  Asterisks indicate statistically significant 





Figure 2.5. Ex vivo detection of the anti-DMPO probe in F98 rat gliomas with streptavidin 
horseradish peroxidase (HRP). Streptavidin-HRP binds to the biotin moiety of the anti-DMPO 
probe. The detection of the anti-DMPO probe is elevated in untreated F98 gliomas administered 
with the anti-DMPO probe (A, brown stain), but not for those treated with OKN-007 (B). There is 
no detection of sustained non-specific IgG contrast agent with streptavidin-HRP (C). 
Magnification = 200×. 
 
 
Figure 2.6. Immunoelectron microscopy detection of the anti-DMPO probe in the plasma 
membrane and cell nuclei in F98 rat gliomas. The biotin moiety of the anti-DMPO probe was 
targeted with gold-anti-biotin. (A) F98 glioma tumor cells administered a non-specific IgG 
contrast agent in vivo, and stained with gold-anti-biotin. Note no detection of gold-anti-biotin 
colloid in either the plasma membrane or cell nucleus. (Bi-iii) Gold-anti-biotin colloids were 
detected within the plasma membrane (black arrows) and cell nuclei of F98 tumor cells 




RONS are now appreciated to play a role in the signaling involved in the regulation of various 
physiological processes, and therefore are essential for maintaining normal cell function. 
However, overproduction and cumulative production of RONS can cause damage to DNA, 
proteins, lipids, and other macromolecules, and induce cell death. Consequently, oxidative stress 
and oxidative damage have been implicated in the pathogenesis and progression of many human 
diseases, including cancer [16]. Although the exact mechanism by which RONS promote 
tumorigenesis remains poorly understood, it is known that DNA damage appears to play a key 
role in cancer development. For instance, RONS induce DNA damage, where the reaction of free 
radicals with DNA generates strand breaks, base modifications, and DNA protein cross-links [2].  
Apart from DNA damage, other mechanisms also have been proposed to explain the connection 
between free radicals and human cancer development, mutation, and transformation. One 
mechanism underlying these actions is the activation of transcription factors such as hypoxia 
inducible factor (HIF)-1α, which leads to the induction of VEGF (vascular endothelial growth 
factor), a key mediator of angiogenesis and tumor progression. Activation of HIF-1α also leads to 
the up regulation of metalloproteinases (MMP), which are important in tumor invasion and 
metastasis [17]. RONS also contribute to tumor survival and progression by facilitating 
immunosuppression. Both reactive species up regulate the activity of myeloid suppressor cells, 
which are abundant in the tumor microenvironment and function to inhibit anti-tumor adaptive 
immunity [18]. Furthermore, various reports have demonstrated that growth factors such as 
PDGF (platelet-derived growth factor) and EGF (epidermal growth factor) can stimulate RONS 
production. RONS, in turn, may directly or indirectly activate several mitogen-activated protein 
kinases (MAPKs) [19, 20], the AKT pathway [21], and the nuclear factor of kappa light 
polypeptide gene enhancer in B-cells (NF-kB) [22]. Also, NF-kB induces iNOS (inducible nitric 
oxide synthase) leading to increased production of reactive nitrogen species, which might result 
49 
 
in generation and accumulation of additional DNA mutations that drive tumor progression (Fig. 
2.7) [23]. Additionally, the expression of iNOS in tumor cells induce the expressions of MMP-1 
and -2, and VEGF-C and -D, and is associated with tumor growth, invasion, and 
lymphangiogenesis [24-25]. 
All tissues and organs are susceptible to free radical damage. The human brain is especially 
vulnerable to free radical attack because of its high oxygen consumption and high concentrations 
of easily oxidizable polyunsaturated fatty acids [26]. In addition, the brain’s antioxidant capacity 
is lower compared with other organs, and thus the brain may be more susceptible to oxidative 
damage [26]. 
Free radical scavengers, such as spin traps, have been studied by many researchers. The most 
widely studied spin trap agents are members of the nitrone class of free radical spin trapping 
agents, in which a nitrone moiety traps ROS in addition to other radical species [27-30]. Nitrone 
spin traps have become increasingly attractive prospects for the treatment of a variety of 
pathological conditions, particularly because of the stable nitroxides that are formed after ROS 
trapping [28, 31]. The nitrone chemical structure in its simplest form can be represented as X-
CH=NO-Y. The N–O group effectively traps oxygen, carbon, and sulfur-centered radicals to 
produce a stable nitroxide radical (-N–O.) [32]. The nitroxide is then readily excreted from the 
body via the kidneys, as is the excess nitrone [33]. 
OKN-007 is a nitrone free radical spin-trapping agent that has exhibited efficacy as a 
neuroprotectant, and is involved in the inhibition of the upregulation of inducible nitric oxide 
synthase and decreasing glutamate excitotoxicity [8]. OKN-007 is a small molecule that can 
traverse the blood-brain barrier, and has anti-inflammatory, antioxidant, and proapoptotic 
properties [8, 34]. Our group has also established that OKN-007 is an effective anticancer agent 
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in rodent pre-clinical glioma models [9-11], and it is currently undergoing clinical trial 
assessment as a new investigational drug for recurrent adult glioblastomas.  
There are several methods that have been used to monitor the levels of free radicals in vitro and in 
vivo. Recently, our group reported the in vivo detection of free radicals in a G261 mouse glioma 
model by combining immuno-spin-trapping (IST) and molecular magnetic resonance imaging 
(mMRI) [6]. It was previously demonstrated in vitro that OKN-007 is an effective free radical 
scavenger for hydroxyl radicals [35].  In the present study we demonstrated, through the use of 
the combined IST and mMRI techniques, that OKN-007 was able to decrease the levels of free 
radicals in a preclinical F98 rat glioma model.  
Specifically, we combined mMRI with a Gd-DTPA-albumin-based contrast agent for signal 
detection with the specificity of an antibody for DMPO nitrone adducts (anti-DMPO probe), to 
detect in vivo free radical levels in untreated and OKN-007 treated adult F98 rat gliomas. As a 
negative control, we used a non-specific IgG antibody covalently bound to the albumin-Gd-
DTPA-biotin construct. To calculate the T1 relaxation, we normalized the T1 relaxation values 
from the tumor area to the contralateral side of the brain in each animal dataset. We used the 
contralateral side of the brain to normalize the T1 relaxation values of the tumor region as we 
detected no significant difference in the T1 relaxation values in the three treatment groups, 120 
minutes after the administration of the either the anti-DMPO probe or non-specific IgG contrast 
agent (UT + anti-DMPO probe, 3426 ± 322.5ms; OKN-007 + anti-DMPO probe, 3363 ± 
573.1ms; UT + IgG probe, 3498 ± 313.0ms). OKN-007 was found to significantly decrease (p = 
0.0411) the levels of free radicals in the treated group compared to the untreated animals 
administered with the anti-DMPO probe. There was no significant difference between the OKN-
007 treated group and the group that received the IgG probe (negative control group) (Fig 2.4A-
D), indicating that OKN-007 reduced free radical levels to undetectable levels. The presence of 
the anti-DMPO probe was also confirmed by targeting the biotin moiety of the anti-DMPO probe 
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with streptavidin HRP (Fig. 2.5A). There was little or no detection of HRP in the OKN-007-
treated sample or the IgG administered tumor tissue (Figs. 2.5B and C). 
We have already demonstrated with immunofluorescence that the anti-DMPO probe binds to 
membrane bound free radicals in GL261 glioma tumor cells [6]. Here we also used 
immunoelectronmicroscopy to demonstrate the presence of the anti-DMPO probe in the 
cytoplasm/membrane and cell nuclei of F98 glioma tumor cells. In this technique, anti-biotin-gold 
was used to bind specifically to the biotin group of the anti-DMPO probe. The IgG contrast agent, 
which also has a biotin moiety, was not detected with the anti-biotin-gold in the plasma 
membrane. Likewise the level of nuclear staining was lower for the IgG contrast agent 
administered sample. However, nuclei staining was found in the glioma cells administered the 
anti-DMPO probe. Due to the size of the anti-DMPO probe, we do not think that this probe could 
be taken up by the cell nuclei. There are three possible other reasons that could account for 
nuclear staining for biotin.  It may be possible that the nuclear positive gold-staining could be 
caused by non-specific staining as a result of secondary labelling of biotin in newly replicated 
DNA [36, 37], or endogenous biotin, which has widely been taken up in the cell nuclei [38], or 
biotin could have come from biodegradation of the anti-DMPO probe. As the control IgG contrast 
agent sample had little staining for biotin, we surmise that the biotin detected in the cell nuclei 
from the glioma sample administered the anti-DMPO probe was from biodegradation of the probe 
which had accumulated in the glioma cells of untreated tumors.  
Redox pathways may be potential targets for cancer therapy. Reduced intracellular RONS levels 
through the administration of antioxidants impairs cell proliferation and survival in some types of 
cancers, such as gliomas [39], colorectal cancer [40], and lymphomas [41]. Martín et al [39] 
demonstrated that N-acetylcysteine could decrease C6 glioma cell proliferation, inducing a cell 
cycle arrest in the G0/G1 phase and markedly up-regulating p21 expression [39]. N-acetylcysteine 
also decreased AKT activity, extracellular signal-regulated kinase 1/2, and the redoxsensitive 
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transcription factor NF-κB, all of which are RONS-related, and seem to be in close connection 
with cell proliferation [39]. 
OKN-007 may share some of the antioxidant mechanisms of action of N-acetylcysteine. It has 
been previously shown that nitrones decrease iNOS (inducible nitric oxide synthase) activity (Fig. 
2.7) [42], which occur in brain tumors [43]. Furthermore, they can also down-regulate cytokines 
[tumor necrosis factor alpha (TNF-α), interferon-gamma (IFN-γ)] and NF-κB expression [44], 
which promotes iNOS expression (Fig. 2.7) [45]. Our data also suggests that the the inhibition of 
the tumor growth by OKN-007 in different preclinical glioma models, as we have reported 
previously [9-11], may in part be due to the reduction of free radicals, as demonstrated in this 
study on F98 gliomas.  
 
2.5 CONCLUSION 
This is the first attempt at detecting in vivo levels of free radicals from a rat glioma model and 
assessing the free radical scavenging capability of a nitrone anticancer agent. OKN-007 was 
found to dramatically reduce free radical levels compared to untreated gliomas. mMRI provides 
the advantage of in vivo image resolution as well as the assessment of the spatial location of 
oxidative stress events in heterogeneous tissues or organs.  
This method can potentially be applied towards other types of cancers for the in vivo assessment 
of macromolecular free radical levels. The results indicate that OKN-007 treatment substantially 







Figure 2.7. Schematic representation of possible antioxidant mechanisms-of-action for the 
anti-cancer agent OKN-007. OKN-007 scavenges radicals associated with tumor (e.g. glioma) 
growth. OKN-007 decreases iNOS (inducible nitric oxide synthase) activity and also down-
regulates some proinflammatory cytokines (TNF-α and IFN-γ) and NF-κB expression, which 
promotes iNOS expression and NO formation. ERK 1/2: extracellular signal-regulated kinase 1/2; 
HIF-1α: hypoxia inducible factor-1α; IFN-γ: interferon-gamma; iNOS: inducible nitric oxide 
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OKN-007 decreases VEGRF-2 levels in a preclinical GL261 mouse glioma model 
 
3.1 INTRODUCTION 
Angiogenesis, the formation of new blood vessels from preexisting vasculature, is a hallmark of 
cancer which plays pivotal roles in tumor development and metastasis [1-3]. Non-invasive and 
quantitative imaging of tumor angiogenesis is critical for lesion detection, patient stratification, 
and monitoring the therapeutic response of cancer patients, including brain tumors [4-5]. 
Physiological angiogenesis is tightly regulated by pro-endothelial and anti-endothelial growth 
factors (i.e. endogenous inhibitors) and occurs by a series of complex and interrelated steps [2, 6-
7]. One of the most potent proangiogenic agents is the well-characterized vascular endothelial 
growth factor (VEGF) [7]. VEGF acts on vascular endothelial cells through compatible receptor 
tyrosine kinases VEGF receptor (VEGFR)-1, -2, and -3 [7]. VEGFR-1 is required for the 
recruitment of haematopoietic stem cells and the migration of monocytes and macrophages, 
VEGFR-2 regulates vascular endothelial function, and VEGFR-3 regulates lymphatic endothelial 
cell function [7]. In addition, VEGFR1 and VEGFR2 are highly expressed in different types of 
cancers such as gliomas [8]. 
Of the many different types of gliomas, glioblastoma (GBM) is the most common, accounting for 
about 40% of all primary brain tumors [9]. GBM is also one of the most vascular [10] and deadly 
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cancers, with a very low 5-year survival rate of 6% [11]. 
A number of studies have shown that overexpression of VEGF and/or VEGFRs correlated with 
poor prognosis in multiple cancer types, including gliomas [12]. Furthermore, it has been also 
reported that intra-tumoral levels of VEGF and VEGFRs correlate with the histological grade of 
gliomas [13]. Knowing the dynamic distribution of VEGFRs, especially VEGFR-2, will lead to 
better understanding of the mechanisms underlying tumor angiogenesis, as well as provide a 
better tool for cancer diagnosis and treatment [14-15].  
Recently, our group used molecular magnetic resonance imaging (mMRI) to evaluate the 
heterogeneous expression of VEGFR-2 in C6 and RG2 rat glioma models, using a specific 
VEGFR-2 contrast agent [16]. The study indicated that the C6 glioma likely have more active 
angiogenesis occurring in the relatively large vessels within the tumor periphery, whereas the 
RG2 glioma may have increased angiogenesis in the microcapillaries within the tumor interior 
[16]. 
Currently, antiangiogenic agents are routinely used for the treatment of patients with gliomas 
[17]. However, despite advances in pharmacological and surgical therapy, gliomas remain an 
incurable disease [17], highlighting the need for new treatment approaches.  
OKN-007 (2, 4-disulfophenyl-PBN; or disodium 4-[(tert-butyl-imino) methyl] benzene-1,3-
disulfonate N-oxide or disufenton; also previously known as NXY-059) is a very effective 
compound against in vivo adult glioma models [18-20], and it is currently undergoing clinical 
trial assessment as a new investigational drug for recurrent adult GBMs. OKN-007 is a small 
molecule that can traverse the blood-brain barrier and has also anti-inflammatory, antioxidant, 
proapoptotic [21-22], and anti-angiogenic properties [19-20]. 
In this study, we combined mMRI with an anti-VEGFR-2 gadolinium-based contrast agent to 
detect in vivo VEGFR-2 levels in untreated and OKN-007 treated adult GL261 mouse glioma 
62 
 
models. Verification of the presence of the probe in tumor tissues and in glioma cell membranes 
through immunofluorescence and electron immunomicroscopy are also presented. 
 
3.2 MATERIAL AND METHODS 
3.2.1 Intracerebral glioma cell implantation 
All animal studies were conducted with the approval of the Oklahoma Medical Research 
Foundation Institutional Animal Care and Use Committee.  As a model for orthotopic intracranial 
brain tumors, a GL261 mouse glioma model was used (n = 17). GL261 mouse glioma cells were 
implanted intracerebrally in C57BL6/J mice. The heads of anesthetized mice were immobilized 
(stereotaxic unit; Kopf Instruments, Tujunga, CA), and with aseptic techniques, a 1 mm burr hole 
was drilled in the skull 1 mm anterior and 2 mm lateral to the bregma on the left side. A 20 μL 
gas-tight Hamilton syringe was used to inject 2 × 10
4
 GL261 cells (in 10 μL of PBS) into the left 
frontal lobe at a depth of 1.5 mm relative to the dural surface in a stereotaxic unit. The cell lines 
were maintained and expanded immediately prior to inoculation.  Following injection, the skin 
was closed with surgical sutures. 
 
3.2.2 OKN-007 treatment 
OKN-007 (2, 4-disulfophenyl-N-tert-butyl nitrone, Ryss Laboratories, Union City, CA) was 
administered to the mice in their drinking water at a concentration of 150 mg/kg/day (0.20% w/v 
for a 20g mouse).  The treatment started at 13-15 days after glioma cell implantation, when the 
tumor volumes were between 10 and 15 mm
3
. The treatment was administered continuously until 
the end of the study. Mice receiving normal drinking water were used as UT controls. The 
amount of OKN-007 consumed by each mouse, which were housed in separate cages, was 
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determined by weighing water bottles each day. No significant deviation was observed in the 
volume of liquid uptake of compound in these mice. The average intake of OKN-007 was 
approximately 140-150 mg/kg/day.  Mortality was recorded daily along the study period to 
calculate the percentage survival of all animals. 
 
3.2.3 Synthesis of anti-VEGFR-2 MRI contrast agent 
The contrast agent, biotin-BSA (bovine serum albumin)-Gd-DTPA, was prepared as previously 
described by our group [23], based on the modification of the method developed by Dafni et al. 
[24]. The estimated molecular weight for the biotin-albumin-Gd-DTPA moiety is ~80 kDa. It is 
estimated that there are 1.3 biotin and 23 Gd-DTPA groups bound to each BSA molecule. Briefly, 
anti-VEGFR-2 mAb (Santa Cruz Biotech, Inc., CA, USA) was conjugated to the albumin moiety 
through a sulfo-NHS (N-succinimidyl-S-acetylthioacetate)–EDC (N-succinimidyl 3-(2-
pyridyldithio)-propionate) link according to the protocol of Hermanson [25]. Each animal was 
injected with 200 μl anti-VEGFR-2-BSA-Gd-DTPA-biotin (VEGFR-2 probe) [16, 26-27] 
intravenously via the tail vein with an amount estimated to be 200 μg anti-VEGFR-2 and 100 mg 
biotin-BSA-Gd-DTPA per injection. The estimated molecular weight of the VEGFR-2 probe is 
232 kDa. For the immunoelectronmicroscopy study, an IgG contrast agent was used for a non-
specific isotype control [16, 27]. 
 
3.2.4 Magnetic resonance techniques 
3.2.4.1 Morphological imaging 
Nude mice were anesthetized and positioned in a stereotaxic cradle. A 30-cm horizontal bore 
Bruker Biospin magnet operating at 7 Tesla (T; Bruker BioSpin GmbH, Karlsruhe, Germany), 
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was used with a S116 gradient set to perform all MRI experiments. A mouse head coil was used 
for signal detection and a 72 mm quadrature volume coil for transmission. Multiple-slice, 
multiple echo (MSME) imaging (FOV= 2.50 x 2.50 cm
2
, TR = 2000 ms, TE = 17.5 or 58.2 ms, 
matrix = 192, averages = 2, slices = 16, slice thickness = 1 mm) was used to calculate tumor 
volumes and to inspect tumor morphology. Starting ten days after the GL261 tumor cells 
inoculation, each mouse brain was imaged in vivo every 2-3 days until the end of the study. 
 
3.2.4.2 Molecular MRI 
Molecular MRI was performed when the tumors volume were close to their maximum tumor 
volumes (120-180 mm
3
). A variable-TR RARE sequence (rapid acquisition with refocused 
echoes, with multiple TRs of 200, 400, 800, 1200 and 1600 ms, TE of 15 ms, FOV of 3.5×3.5 
cm2, matrix size of 256×256 and a spatial resolution of 0.137 mm) was used to obtain T1-weighted 
images before and after administration of probe or control contrast agents.  
 
3.2.4.3 Calculation of relative probe concentration 
Relative probe (contrast agent) concentrations were calculated to assess the levels of VEGFR-2 in 
each animal. A contrast difference image was created from the pre- and (120 minutes) 
postcontrast datasets for the slice of interest, by computing the difference in signal intensity 
between the post-contrast and the pre-contrast image on a pixel basis. From a difference image, 
ten regions of interest (ROI) of equal size (0.05cm
2
) were drawn within areas with the highest T1 
relaxation in the tumor parenchyma and contralateral side of the brain for each animal after the 
VEGFR-2 probe injection at the TR 800 ms. The values obtained from the ROIs in the tumor 
regions were normalized to the corresponding contralateral sides. The T1 relaxation value of the 
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specified ROIs was computed from all the pixels in the ROI by the following 
equation [28] (processed by ParaVision 4.0, Bruker): S(TR) = S0(1 − e
− TR / T1
), where TR is the 
repetition time, S0 is the signal intensity (integer machine units) at TR ≫ T1 and TE = 0, and T1 is 
the constant of the longitudinal relaxation time. An overlay of the contrast difference image and 
T1-weighted image was generated using the 3D Analysis Software for Life Sciences Amira® 
(Fei, Hillsboro, Oregon). 
 
3.2.5 Fluorescence staining 
The whole brain of each rat from each treatment group was removed and fixed in 4% 
paraformaldehyde solution in phosphate buffered saline, then embedded in Optimal Cutting 
Temperature (OCT) compound and frozen in liquid nitrogen. Frozen tissue blocks were sectioned 
at 10 μm, mounted on positive-charged slides, and air-dried for 30 minutes. The tissue samples 
were permeabilized with 0.01% saponin in PBS (PBS/SAP) (10 minutes at 20°C) and incubated 
in a mixture of 3% bovine serum albumin and 5% normal donkey serum (host animal of the 
conjugated detection antibody) in PBS/SAP (1 hour at 20°C). Saponin was kept in all incubation 
buffers throughout the staining procedure, to ensure a proper penetration of the antibodies. 
Saponin exclusively removes cholesterol molecules from lipid-containing structures, leaving 
stable holes large enough for penetration of antibodies. 
Next, the tissue sections were incubated with anti-CD31 antibody (BD Pharmingen Purified Rat 
anti-mouse CD31, catalog number: 550274) overnight at 4°C. The samples were washed 3 × 10 
minutes in PBS/SAP, and incubated for 1 hour at 20°C with combinations of appropriate 
detection antibodies conjugated with fluorescein isothiocyanate and Cy3 diluted 1:100 in 1% 
bovine serum albumin in PBS/SAP. After washing as above, the sections were mounted between 
glass slides and coverslips using Vectashield hardset mounting medium (Vector Laboratories, 
66 
 
Burlingame, CA) containing TO-PRO-3 iodine (Molecular Probes, Eugene, OR) as nuclear 
counterstain. 
As negative controls for polyclonal antibody staining, the primary antibodies were replaced with 
equivalent amounts of rat nonimmune serum. Specimens were examined by epifluorescence 
confocal imaging using a Nikon C1 confocal laser-scanning unit equipped with a three-laser 
launcher (488, 543, and 633 nm emission lines) installed on an Eclipse TE200-U inverted 
microscope (Nikon, Melville, NY). Images were taken with a ×20 plan achromat objective (NA 
0.46). Image collection parameters (neutral density filters, pinhole, and detector gains) were kept 
constant during image acquisition, to make reliable semiquantitative comparisons between the 
linear and branched regions of the arteries. 
 
3.2.6 Gold labeling immunoelectron microscopy 
Brain tissue was obtained from GL261 glioma bearing mice that were administered either 
VEGFR-2 probe or a non-specific IgG contrast agent with gadolinium(Gd)-DTPA(diethylene 
triamine penta acetic acid)-albumin construct. Tissues were removed and cut to size of about 2cm 
and 3-5mm thick then fixed in 4% paraformaldehyde + 0.1% glutaraldehyde in 0.1M phosphate 
buffer (PB) for 1 hour at room temperature or at 4°C, washed thoroughly with with PB (pH 7.3). 
Tissue was trimmed further to 1-2mm pieces. Osmication was omitted for labelling procedure. 
Dehydration was in an ethanol series (50%, 70%, 80%, at 15 min each). Tissue was placed in 2:1 
LR White resin (Electron Microscopy Sciences, PA) to 70% ethanol for 1 hour to avoid tissue 
shrinkage, and then further infiltrated in 100% LR White for 1 hour, overnight, and then two 
changes for 30 minutes. Tissue was added to gelatin capsules and LR White polymerized at 50°C 
for 24 hours. Gold-silver sections were placed on nickel grids coated with formvar or 
colloidin.  Sections on grids were protein blocked in Aurion goat gold conjugate (Electron 
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Microscopy Sciences, PA) for 30 minutes, washed in PBS-0.2% bovine serum albumin 3x for 5 
minutes at pH 7.4 (Electron Microscopy Sciences, PA). Aurion ultra small gold conjugate – goat 
anti-Biotin (Electron Microscopy Sciences, PA) in PBS-0.2% BSA-c was applied at 1:100 for 
overnight at 4°C or for 4 hours at room temperature. Grids were washed in PBS-0.2% BSA-c (pH 
7.4), 6x for 5minutes; in PBS, 3x for 5 minutes; in distilled water 5x for 2 minutes. Silver 
enhancement was done by placing grids on a droplet of Aurion R-Gent SE-EM enhancement 
mixture (Electron Microscopy Sciences, PA) for 90 minutes, then washed in distilled water. 
Controls involved sections with no secondary antibody (anti-Biotin) and no silver enhancement. 
Sections were stained with uranyl acetate for 15 minutes followed by lead citrate for 3 minutes. 
Sections were viewed with a Zeiss T109 electron microscope operated at 80kV and equipped with 
a Gatan digital camera and micrograph acquisition software. 
 
3.2.8 Statistical analysis 
Statistical analyses were performed using the Graph Pad Prism 6 (GraphPad Prism 6 Software, 
San Diego, CA, USA). Tumor volumes and the VEGRF-2 levels were reported as the mean ± 
standard deviation. Student t-tests (independent-samples, two-tailed t-test) were used to assess the 
differences between means of untreated and OKN-007 treated GL261 glioma mice. For statistical 
analysis, Kaplan-Meier survival curves and Log-rank (mantel-cox) test were used to compare the 
survival times among the untreated and OKN-007 treated groups. All p values <0.05 were 








Starting ten days after the GL261 tumor cell inoculations, all animals from each group were 
imaged in vivo every 2-3 days until the end of the study. The tumor volumes of ONK-007-treated 
animals were significantly smaller (p = 0.0054; 32.95 ± 7.130, n=4) than the untreated group 
(103.0 ± 16.96, n=7) at day 21 after tumor cell injection (Fig 3.1A-C).  
For the entire study, animal survival was assessed by comparing OKN-007–treated animals with 
untreated animals. OKN-007-treated mice were found to survive significantly longer (p = 0.0005; 
median survival = 30 days; n = 7), compared with untreated animals (median survival = 22 days; 
n = 10) (Fig 3.1D). 
Representative examples of images obtained in GL261 glioma-bearing mice are shown in Fig. 
3.2.  T2-weighted and T1-weighted morphological images obtained before injection of the 
VEGFR-2 probe are shown in Fig 3.2A and Fig. 3.2B respectively. A difference image, which is 
the subtraction between the T1 images of pre- and 2 hrs after injection of the contrast agent, 
shows increased anti-VEGFR-2 probe accumulation in Fig. 3.2C, along with representative ROIs 







Figure 3.1. Effect of OKN-007 on tumor volumes and survival for GL261 tumor bearing 
mice. Representative T2-weighted MR images of UT (A) and OKN-007 (B) treated GL261 
gliomas. (C) The OKN-007-treated animals demonstrated significantly smaller tumors (p = 
0.0054) when compared with UT animals. (D) The OKN-007-treated animals demonstrated 
significantly longer survival times (p = 0.0005, median survival = 30) when compared with UT 
animals (median survival = 22). Values are represented as means ± SD. Asterisks indicate 





Figure 3.2. Morphological MR images obtained before and 2 hrs after injection of anti-
VEGFR-2 probe (contrast agent) in a F98 rat glioma moldel. Representative T2-weighted (A) 
and T1-weighted image (B) before injection of the VEGFR-2 probe. (C) Representative difference 
image, which is the subtraction between the T1 images of pre- and 2 hrs after injection of the 
contrast agent. The dark regions in the tumor depict areas of increased uptake of the anti- 
VEGFR-2 probe. Representative ROIs in the tumor and contralateral side of the brain are 
illustrated as circles in each region. The tumor is delineated  by a dotted line in each panel. 
 
There were differences in the levels of VEGFR-2 detected in the two different treatment groups. 
OKN-007 was found to significantly decrease (p = 0.04137) the levels of VEGFR-2 detected in 
the treated group (2.54 ± 2.02) compared to the untreated animals (10.12 ± 2.25) (Fig 3.3). 
The fluorescence agent Cy3 (red) attached to streptavidin targets the biotin moiety of the anti-
VEGFR-2 probe that is present in ex vivo excised tumor tissue from a GL261 glioma-bearing 
mouse administered the anti- VEGFR-2 probe in vivo. Co-localization (represented as yellow-
orange regions) of the anti- VEGFR-2 probe (red) with the endothelial cell marker CD31 (green) 
was observed in some areas of glioma tissue from GL261 glioma-bearing mice administered the 








Figure 3.3. mMRI detection of VEGFR-2 in a GL261 mouse glioma model.  Representative 
MR images from: (A) Untreated and (B) OKN-007 treated GL261 mouse gliomas. (Ai-Bi) T2-
weighted images of GL261 glioma. (Aii-Bii) T2-weighted images overlayed with a difference T1-
weighted image (red), which was the subtraction between the 2 hr post-contrast and the pre-
contrast images after injection of either the anti-VEGFR-2 probe contrast agent. Overlays of the 
contrast difference images and the T2-weighet images were generated using the 3D Analysis 
Software for Life Sciences Amira®. (C) OKN-007 was found to significantly decrease (p = 
0.4137) (2.54 ± 2.02) the levels of VEGFR-2 in the treated group compared to the untreated 
animals (10.12 ± 2.25). Values are represented as means ± SD. Asterisks indicate statistically 




Figure 3.4. Ex vivo detection of the anti-VEGFR-2 probe and colocalization with endothelial 
cell marker CD31 in untreated and OKN-007-treated GL261 mouse gliomas. Fluorescence 
images of the anti-VEGFR-2 probe (red) and the endothelial marker CD31 (green) in untreated 
(Ai-Aiii) GL261 tumor-bearing animals and OKN-007-treated (Bi-Biii) GL261 tumor-bearing 
animals. Note colocalization (yellow-orange) of the anti- VEGFR-2 probe with some endothelial 
cells in the untreated group. 
 
Ex vivo immunoelectron microscopy of GL261 mouse glioma tissues after post-embedding 
incubation with gold-labeled anti-biotin antibody was performed to determine the sub-cellular 
localization of the anti-VEGFR-2 probe (Fig 3.5). The gold-labeled anti-biotin was found to be 
distributed within the endothelial cell and glioma cell plasma membrane/cytoplasm, as well as the 
nuclei of the GL261 tumor cells in mice administered the anti- VEGFR-2 in vivo (Fig 3.5A).  A 






Figure 3.5. Electron immunomicroscopy detection of the anti-VEGFR-2 probe in the 
endothelial plasma membrane/cytoplasm and cell nuclei within GL261 rat gliomas. (A) 
Electron immunomicroscopy of a GL261 glioma-bearing mouse administered the anti-VEGFR2 
probe. The biotin moiety of the anti-VEGFR-2 probe was targeted with gold-anti-biotin. Note 
uptake of the gold-anti-biotin in the endothelial plasma membrane/cytoplasm (black arrows) and 
the glioma cell plasma membrane/cytoplasm (white arrows). Also note increased gold-anti-biotin 
in the endothelial and glioma cell nuclei. (B) GL261 glioma-bearing mouse administered the non-
specific IgG-albumin-Gd-DTPA-biotin probe (Control). Note some uptake of the gold-anti-biotin 
in the endothelial cell nucleus. Scale bar = 1µm. Magnification = 20,000×. 
 
3.4 DISCUSSION 
Angiogenesis, the formation of new blood vessels, is a critical step during tumorigenesis and 
represents a pathological hallmark of cancer [1], and plays a crucial role in glioma development 
and growth [29].  
Briefly, the start of the angiogenesis process requires some exogenous angiogenic  stimulus, such 
as hypoxia, current metabolic requirements, and tumor growth. More than 25 different growth 
factors and cytokines related to the induction of angiogenesis have been reported [30]. The 
production of these proangiogenic factors is a result of genetic alterations or is induced by 
hypoxia. Intratumor hypoxia occurs at the time when there is an imbalance between oxygen 
supply and demand, due to irregular and chaotic blood flow [31]. 
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Furthermore, when a solid tumor, such as a brain tumor, grows larger than a critical size (1-2mm 
in diameter), it must recruit new blood vessels to supply the required oxygen and nutrition levels 
necessary for its survival and proliferation [17, 32]. This process comprises the formation of new 
blood vessels from preexisting ones, and is a crucial step in the progression of cancer from a 
small and localized neoplasm to a highly aggressive tumor [17]. Additional details about the 
angiogenesis process in gliomas can be found in a number of outstanding review articles [17, 29, 
33-35]. 
Gliomas are highly vascularized tumors [35]. Furthermore, the formation of abnormal tumor 
vasculature and glioma cell invasion along white matter tracts are proposed to be the major 
causes of the therapeutic resistance of these tumors [17]. Thus, inhibition of angiogenesis has 
emerged as a promising strategy for the treatment of brain cancers.  
In this study, we demonstrated through conventional and molecular MRI that OKN-007 inhibited 
the tumor levels of VEGFR-2, tumor growth, and increased survival time in treated GL261 mouse 
gliomas when compared to the untreated group. 
Our group has already established that OKN-007 is an effective anti-cancer agent in rodent pre-
clinical models for adult GBMs, including F98 [19], U87 [19], and C6 [18, 20] glioma models. 
Furthermore, in an orthotopic rat F98 glioma model and a human U87 xenograft model in 
athymic rats, OKN-007 significantly increased the survival of treated versus untreated rats [20].  
Similarly to our previous studies, OKN-007 was also able to decrease the tumor volumes in the 
GL261 mouse glioma model. In the present study, the tumor volumes of OKN-007-treated 
GL261 gliomas were significantly smaller (p = 0.0054) when compared to the untreated group 
(Fig 3.1C).  
The survival time of GL261-tumor bearing mice was also significantly increased after OKN-007 
therapy, as we also have previously reported in other adult glioma models [19-20]. The OKN-
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007-treated group (n = 7) had a median survival of 30 days, which was significantly longer (p = 
0.0005) than the median survival of 22 days for the untreated group (n = 10) (Fig. 3.1D). OKN-
007 was able to increase the survival time by 8 days in the treated group compared to the 
untreated animals. Considering that one mouse month is equivalent to ∼2.6 human years, based 
on a 4-year maximum life span [36], OKN-007 could potentially increase survival time in adult 
GBM patients by ~7-8 months. 
There are several methods that have been used to monitor the levels of VEGFR-2 in vitro and in 
vivo. Recently, our group reported the in vivo characterization and distribution of VEGFR-2 in C6 
[16, 27] and RG2 [16] glioma models using molecular magnetic resonance imaging (mMRI) and 
an anti-VEGFR-2 gadolinium-based contrast agent. MRI signal enhancement of the VEGFR-2 
probe in the RG2 tumor interior was more than twice that for the C6 tumor interior, suggesting 
more VEGFR-2 from microvessels inside the RG2 tumor [16]. However, compared to C6 
gliomas, RG2 gliomas have a relatively more homogeneous pattern for VEGFR-2 levels in the 
tumor overall [16]. In the C6 glioma, distinctively higher levels of VEGFR-2 were found in peri-
tumor and peri-necrotic regions compared to tumor interior regions [27].  
It was also previously demonstrated in vivo that OKN-007 is an effective anti-angiogenic 
compound, for decreasing the microvessel density and HIF-1α levels in both F98 and U87 glioma 
models [19] and the levels of VEGFR-2, as determined from Western blots, in C6 rat gliomas 
[20].  In the present study we confirmed using the mMRI technique, that OKN-007 was also able 
to decrease the levels of VEGFR-2 in a preclinical GL261 mouse glioma model (Fig 3.3). 
Specifically, we combined mMRI with a Gd-DTPA-albumin-based contrast agent for signal 
detection with the specificity of an antibody for VEGFR-2 (anti-VEGFR2 probe), to detect in 
vivo VEGFR-2 levels in untreated and OKN-007 treated adult GL261 mouse gliomas. To 
calculate the T1 relaxation, we normalized the T1 relaxation values from the tumor area to the 
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contralateral side of the brain in each animal datasets.  We used the contralateral side of the brain 
to normalize the T1 relaxation values of the tumor region as we detected no significant difference 
(p = 0.1824) in the T1 relaxation values in the two treatment groups, 120 minutes after the 
administration of the anti-VEGFR-2 probe. 
We have already demonstrated with immunofluorescence that the anti-VEGFR-2 probe binds to 
the VEGFR-2 present on tumor cells and endothelial cells in a rat C6 glioma model [27]. In the 
present study in the mouse GL261 glioma model, the fluorescence staining at 2 hours post 
administration of the probe confirmed the distribution of VEGFR2 similarly to our previous study 
[27]. Furthermore, the probe showed localization with the endothelial marker CD31 (Fig 3.4A). 
Here we additionally used immunoelectron microscopy to demonstrate the presence of the anti-
VEGFR-2 probe in the cell membrane/cytoplasm and cell nuclei of the endothelial cells and 
GL261 glioma tumor cells (Fig. 3.5A). During this technique, anti-biotin-gold was used to bind 
specifically to the biotin group of the anti-VEGFR-2 probe. The IgG contrast agent, which also 
has a biotin moiety, was not detected at very high levels with the anti-biotin-gold in the plasma 
membrane/cytoplasm of endothelial or glioma cells. Likewise the level of nuclear staining was 
less for the IgG contrast agent administered sample in the endothelial and glioma cells (Fig. 
3.5B). However, more nuclear staining was found in the endothelial and glioma cells 
administered the anti-VEGFR-2 probe. Due to the size of the anti-VEGFR-2 probe, we do not 
think that this probe could be taken up by the cell nuclei. There are three possible other reasons 
that could account for nuclear staining for biotin.  It may be possible that the nuclear positive 
gold-staining could be caused by non-specific staining as a result of secondary labelling of biotin 
in newly replicated DNA [37-38], or endogenous biotin, which has widely been taken up in the 
cell nuclei [39], or biotin could have come from biodegradation of the anti- VEGFR-2 probe. As 
the control IgG contrast agent sample had little staining for biotin, we surmise that the biotin 
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detected in the cell nuclei from the glioma sample administered the anti- VEGFR-2 probe was 
from biodegradation of the probe which had accumulated in the glioma cells of untreated tumors. 
Figure 3.6 depicts the possible anti-angiogenic mechanism of action of OKN-007 in glioma 
models. We already know that OKN-007 decreases levels of VEGFR-2 [20] and HIF-1α [19] in 
rat gliomas, and that nitrones such as PBN (α-phenyl-tert-butyl nitrone) decrease NF-κB in a 
mouse endotoxemia model [40]. There is also evidence that OKN-007 effectively traps free 
radicals in vitro [41]. Consequently, based on the possible mechanisms-of-action and our data 












Figure 3.6. Schematic representation of possible anti-angiogenic mechanisms of action for 
the anti-cancer agent OKN-007. (1) VEGF is ubiquitously expressed in almost all tumors. 
Glioma cells have been demonstrated to secrete VEGF, which leads to increased angiogenesis 
[42]. (2) VEGF exerts its action through binding to VEGFR-2, leading to autophosphorylation of 
tyrosine residues in the cytoplasmic domain of VEGFR-2 and driving downstream pathway such 
as PI3K/AKT and MAPK to promote endothelial cells proliferation and migration (3). VEGF also 
stimulates reactive oxygen and nitrogen species (RONS) production via Rac1-mediated NADPH 
oxidase activation (4) [43] and also increases mitochondria-derived hydrogen peroxide (H2O2) (5) 
[44]. (6) RONS, in turn, potentiate VEGFR phosphorylation [43]. RONS can also upregulate 
VEGF secretion and VEGFR expression through induction of transcription factors HIF-1α 
(hypoxia-inducible factor-1α) (7) [44-46]. (8) Under hypoxic conditions, the active HIF-1α 
recognizes and binds to cis elements in the promoter of genes that mediate angiogenesis, such as 
the gene encoding VEGF [47]. (9) NF-kB (nuclear factor of kappa light polypeptide gene 
enhancer in B-cell) is normally under strict regulation by its sequestration in the cytoplasm in 
association with a heterotrimeric complex of NF-kB with the inhibitor of kB (IkB) [47]. (10) 
Generation of reactive oxygen and nitrogen species (RONS) and activation of PI3 kinase–AKT 
pathway can converge and activate NF-kB. NF-kB also activates several genes that mediate 
angiogenesis, such ELR
+
 CXC chemokines [47]. OKN-007 decreases levels of VEGFR-2 [20] 
(11) and HIF-1α [19] (12) in rat gliomas, and that nitrones such as PBN (α-phenyl-tert-butyl 
nitrone) decrease NF-κB (13) in a mouse endotoxemia model [40]. There is also evidence that 
OKN-007 effectively traps free radicals (14) in vitro [41]. Consequently, based on the possible 
mechanisms-of-action and our data reported in this study, OKN-007 is an effective agent that can 
inhibit tumor angiogenesis (15). The schematic is a modification of combined schemes obtained 
from Oxidative Medicine and Cellular Longevity, Article ID 374963, Zhou Y  et al. (2013) 
[Copyright (2013) with permission from Hindawi Publishing Corporation] [48], and from Nature 
Medicine, 11(9):925-7, Strieter RM. (2005) [Copyright (2005) with permission from Nature 
Publishing Group] [47]. 
 
3.5 CONCLUSION   
This is the first attempt at detecting in vivo levels of VEGFR-2 in a mouse GL261 glioma model 
and assessing the anti-angiogenic capability of an anticancer nitrone. Our study confirmed that in 
vivo VEGFR2 levels can be monitored and can be used to assess the efficacy of an anti-
angiogenic therapy. 
This method can potentially be applied towards other types of cancers for the in vivo assessment 
of VEGFR-2 levels, and assess various anti-angiogenic agents. The results indicate that OKN-007 
treatment substantially decreased VEGFR-2 levels in a GL261 glioma model, and can be 
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Inhibition of pediatric glioblastoma tumor growth by the anti-cancer agent OKN-007 in 
orthotopic mouse xenografts 
 
4.1 INTRODUCTION 
High grade gliomas (HGG) represent one of the most common central nervous system (CNS) 
tumors among adults. This contrasts significantly to the pediatric population where HGGs only 
comprise approximately 8–12% of all primary CNS tumors [1]. These tumors are classified by 
the World Health Organization (WHO) as either grade III or IV meaning that they are highly 
malignant tumors with characteristic features such as hypercellularity, nuclear atypia, and high 
mitotic activity with or without microvascular proliferation and necrosis [2]. The most common 
pediatric HGGs include anaplastic astrocytoma (WHO grade III) and glioblastoma (GBM; WHO 
grade IV). Pediatric glioblastoma (pGBM) is one of the leading causes of cancer-related deaths in 
children [3] with a median overall survival for patients of 11 months [4]. Despite improvements 
in neurosurgery, radiotherapy, and chemotherapy, the outcome for children with pediatric HGG 
remains poor [5-6]. No effective chemotherapy regimens have yet been identified for any 
pediatric HGG [5]. Furthermore, novel molecularly targeted agents have demonstrated little 
efficacy in early phase clinical trials [7-9], highlighting the need for new treatment approaches. 
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Similarly, the improvement of in vitro and in vivo models for pediatric HGGs is also needed. 
Tumor cell lines and animal models derived from CNS tumors are essential tools to study the 
biology of the disease, to comprehend the mechanisms of resistance to therapy, and to carry out 
preclinical therapeutic testing. There is abundant information on animal models of adult HGG 
[10-13], including chemically induced, genetically engineered mice, and xenograft models [10]. 
However, to date only a few pediatric brain tumor models have been established and/or 
characterized [14-21]. 
We have shown that the anti-cancer agent OKN-007 (OKlahoma Nitrone-007; disodium 4-[(tert-
butyl-imino) methyl] benzene-1,3-disulfonate N-oxide or disufenton) is very effective against 
adult gliomas in preclinical models [12,22-23], and it is currently undergoing clinical trial 
assessment as a new investigational drug for recurrent adult glioblastomas. OKN-007 is a small 
molecule that can traverse the blood-brain barrier and has anti-inflammatory, antioxidant, and 
proapoptotic properties [24-25]. In an orthotopic rat F98 glioma model and a human U87 
xenograft model in athymic rats, OKN-007 significantly increased the survival of treated versus 
untreated rats [23]. Tumor volumes in both of these models were significantly decreased in 
treated compared to untreated animals based on magnetic resonance imaging (MRI) assessment 
[23]. 
MRI has been used in preclinical [14-15] and clinical [26-33] studies to diagnose and predict 
therapy outcomes for pediatric brain tumors. The techniques most commonly used include in vivo 
1
H magnetic resonance spectroscopy (
1
H-MRS) [34-36], diffusion-weighted imaging (DWI) [37-
38], and arterial spin labeling perfusion (ASL) [39]. 
1
H-MRS has been used in research and 
clinical settings to measure metabolite levels in the brain, and is well suited to perform the 
diagnosis, characterization, and assessment of tumor response to treatment [40]. DWI can 
qualitatively and quantitatively assess molecular motion on the basis of microstructural 
organization of tissues by characterizing water mobility [41], and can provide a more complete 
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evaluation of cellular and metabolic information about human brain cancer [42]. ASL allows the 
assessment of measuring tumor blood flow [43], which assists in the characterization of tumor 
grade [39] and response to cancer therapy [44]. 
Here we describe the MRI characterization of a novel orthotopic xenograft pediatric HGG mouse 
(IC-3752GBM) model and the effects of OKN-007 to inhibit in vivo pediatric glioblastoma IC-
3752GBM tumor growth using conventional (morphological imaging) and advanced MRI 
techniques (
1
H-MRS, DWI, and ASL). Immunohistochemical staining was also used to evaluate 
the levels of tumor-related proteins and to assess tumor cell proliferation. To the best of our 
knowledge, the current study is the first report of MRI characterization of an orthotopic xenograft 
murine model of pGBM, and the assessment of the anti-cancer agent, OKN-007, in a pGBM 
model. 
 
4.2 MATERIAL AND METHODS 
4.2.1 Brain tumor specimen 
A fresh tumor specimen (IC-3752GBM), from a 5-year-old female who underwent craniotomy at 
the Texas Children's Hospital, was obtained in a cryostat laboratory with signed consent 
following an Institutional Review Board-approved protocol. Final pathological diagnosis was 
consistent with pediatric glioblastoma (pGBM) [45]. The tumor sample was directly implanted 
into right cerebral cortex of immunedeficient mice. Xenograft tumor cells harvested from donor 
mice were  passaged in nude mice via six subsequent implantations as we described previously 
[45-46] Institutional Animal Care and Use Committee approvals were obtained for the mouse 





4.2.2 Intracranial mouse brain tumor model 
The animal studies were conducted with approval from the Institutional Animal Care and Use 
Committee of the Oklahoma Medical Research Foundation. The passaged pediatric glioblastoma 
cells IC-3752GBM were implanted intracerebrally in athymic nude mice (n= 19). The heads of 
anesthetized mice were immobilized (stereotaxic unit; Kopf Instruments, Tujunga, CA), and with 
aseptic techniques, a 1 mm burr hole was drilled in the skull 1 mm anterior and 2 mm lateral to 
the bregma on the left side. A 20 μL gas-tight Hamilton syringe was used to inject 5-10 × 10
6 
IC-
3752GBM cells/mL suspended in 4 µL in cell culture media with 1.0% agarose into the left 
frontal lobe at a depth of 1.5 mm relative to the dural surface in a stereotaxic unit. The cell lines 
were maintained and expanded immediately prior to inoculation. Following injection, the skin 
was closed with surgical sutures. The animals were divided into two groups: OKN-007–treated (n 
= 11) and untreated (n = 8) groups. Both groups were stratified to ensure that tumor sizes were 
similar before treatment started in the treated group. 
 
4.2.3 OKN-007 treatment 
OKN-007 (Ryss Laboratories, Union City, CA) was administered to the mice in their drinking 
water at a concentration of 150 mg/kg/day (0.20% w/v for a 20g mouse). The treatment started 
when the tumor volumes were between 10 and 15 mm
3
, and was administered continuously until 
the end of the study. Mice receiving normal drinking water were used as untreated controls. The 
amount of OKN-007 consumed by each mouse, which were housed in separate cages, was 
determined by weighing water bottles each day. No significant deviation was observed in the 
volume of liquid uptake of compound in these mice. The average intake of OKN-007 was 
approximately 130-150 mg/kg/day. For the entire study, the therapeutic response to OKN-007 
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was evaluated as either responsive (OKN-007-R) or non-responsive (OKN-007-NR). Mortality 
was recorded daily during the study period to calculate the percentage survival of all animals. 
 
4.2.4 Magnetic resonance techniques 
4.2.4.1 Morphological imaging 
Nude mice were anesthetized and positioned in a stereotaxic cradle. A 30-cm horizontal bore 
Bruker Biospin magnet operating at 7 Tesla (T; Bruker BioSpin GmbH, Karlsruhe, Germany), 
was used with a S116 gradient set to perform all MRI experiments. An EPI (echo planar imaging) 
transceiver 
1
H 50W coil with a 38.0 mm inner diameter was used for signal transmission and 
detection. Multiple-slice, multiple echo (MSME) imaging (FOV= 2.50 x 2.50 cm
2
, TR = 2000 
ms, TE = 17.5 or 58.2 ms, matrix = 192, averages = 2, slices = 16, slice thickness = 1 mm) was 
used to calculate tumor volumes and to inspect tumor morphology. Multi slice spin echo T1-
weighted images (TR = 1000.0 ms, TE = 14 ms, FOV = 2.50 × 2.50 cm
2
, averages=2, slices=16, 
matrix size = 256 × 256) were also performed and acquired before and 15 min after intravenous 






H-MRS was acquired using a PRESS (Point REsolved SpectroScopy) sequence with a TE of 
24.0 ms, a TR of 2500.0 ms, 512 averages, and a spectral width of 4006 Hz. A non-suppressed 
MR spectrum was acquired beforehand by applying eddy-current correction to maximize signal 
intensity and decrease the peak linewidths. Water was suppressed with a VAPOR (variable power 
radio frequency pulses and optimized relaxation delays) suppression scheme. In all cases, the 
peak width (full width at half maximum) of the water peak was less than 30 Hz following 
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localized shimming, which was conducted by using first and second order adjustments with 
Fastmap. A cubic voxel of 2.0 x 2.0 x 2.0 mm
3
 was positioned in either the tumor or the 
contralateral normal brain tissue, while maximizing the amount of tumor tissue present in the 
voxel at all times.  
To analyze the MRS data, an in-house Mathematica program was used (version 6.0, Wolfram 
Research, Champaign, IL, USA). The spectra were scaled in ppm by calibrating against the water 
peak (4.78 ppm). The major brain metabolic peaks were identified as:  N-acetylaspartate (NAA) 
at 2.02 ppm, choline (Cho) at 3.22 ppm, creatine (Cre) at 3.02 ppm, and mobile lipids at 1.3 ppm 
(Lip1.3) for the methylene group (-CH2-) and 0.9 ppm (Lip0.9) for the methyl group (-CH3) in the 
tumor tissue. The peak area measurements of the metabolites were used to calculate the following 
























4.2.4.3 Diffusion-Weighted Imaging 
A coronal axial multi-slice DWI sequence covering the entire tumor was performed using an echo 
planar imaging–based pulse sequence with the following parameters: TR = 4000 ms, TE = 51.1 
ms, matrix size = 128 × 128, slice thickness = 1mm, diffusion gradient duration = 4 ms, diffusion 
gradient separation = 14 ms. Five images were obtained with different gradient scalings, resulting 
in b-values of 100, 200, 500, 700, and 850 s/mm
−2
. ADC maps were generated for all the slices in 
which the tumor was observed. The apparent diffusion coefficient (ADC) values were obtained 






4.2.4.4 Arterial spin-labeling perfusion 
Perfusion maps were obtained on a single axial slice of the brain located on the point of the 
rostro–caudal axis where the tumor had the largest cross-section. The imaging geometry was a 
25.6 × 25.6 mm
2
 field-of-view (FOV) of 2 mm in thickness, with a single shot echo-planar 
encoding over a 64 × 64 matrix. An echo time (TE) of 13.5 ms, a repetition time (TR) of 18 s, and 
an inversion time (TIR) of 26.0 ms were used, and images were not submitted to time averaging. 
To obtain perfusion contrast, the flow alternating inversion recovery scheme was used. Briefly, 
inversion recovery images were acquired using a slice-selective inversion of the same geometry 
as the imaging slice or a nonselective inversion slice concentric with the imaging slice with a 
slice package margin of 5.0 mm. For each type of inversion, 22 images were acquired with 
inversion times evenly spaced from 26.0 ms to 8,426.0 ms (with an increment of 400 ms between 
each TIR). CBV (cerebral blood flow) values were obtained by drawing a single freehand ROI 
along the border of the tumor normalized to the contralateral normal brain to obtain normalized 
relative CBF (rCBF) values. Negative ASL CBF values were assumed to be zero [47].  
 
4.2.5 Gross and microscopic histology 
Necropsies were performed on all mice. The extent of tumor at necropsy was evaluated by gross 
and microscopic examination of the brain for each animal from the untreated and OKN-007–
treated groups. Brain tissues were fixed in 10% phosphate buffered formalin, embedded in 







Immunohistochemical staining was performed using an automated immunostainer (Leica, Bond-
III, Leica, Buffalo Grove, IL) with the following primary polyclonal antibodies: platelet-derived 
growth factor receptor alpha (PDGFRα) (1:1000 dilution, rabbit polyclonal, clone ab61219, 
ABCAM), decorin (1:500 dilution, rabbit polyclonal, clone LS-B 8177 / 45156), LSBIO 
LifeSpan BioSciences), heparan sulfate sulfatase SULF2 (1:100 dilution, rabbit polyclonal,  clone 
AV49338, Sigma Aldrich), and CD31 (1:25 dilution, rabbit polyclonal, clone ab28364, ABCAM, 
Ki-67 (1:100 dilution, rabbit polyclonal, clone PA5-19462, Thermo Fisher Scientific, IL). All 
antibodies were initially optimized on control tissues, and positive and negative controls were 
processed in parallel to the tissue sections. 
 
4.2.7 IHC Scoring 
All IHCs were analyzed using the Aperio ScanScope Image Analysis System (Aperio, Vista, 
CA). PDGFRα, SULF2, and decorin IHCs were analyzed using a Positive Pixel Count algorithm 
with the Aperio ImageScope viewer. Only areas containing tumor tissue were analyzed for IHC 
expression. Areas without tumor tissue and areas with necrosis or significant artifacts (e.g. tissue 
folding) were deselected and excluded from analysis. The number of positive pixels was divided 
by the total number of pixels (negative and positive) in the analyzed area, and multiplied by 100, 
to derive the percentage of positive pixels.  
Microvessel density (MVD, number of vessels per mm
2
) and Mean Vessel Area (MVA, Vascular 
area/2 + lumen area), using CD31 as a marker, were determined using an Aperio microvessel 
analysis algorithm. Three representative non-overlapping regions of interest (ROIs) for tumor 
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samples were randomly selected, and the MVD and MVA were quantified for each animal from 
both untreated and OKN-007–treated groups. 
An Aperio ScanScope Image Analysis System was also used to determine the KI-67 labeling 
index (Ki-67 LI). Three ROIs with the highest number of labeled nuclei were identified in each 
case. Ki-67 LI was determined by counting 1000 cells and expressing this as the number of 
labeled cells per 1000 cells [48] for each animal from both untreated and OKN-007–treated 
groups. Labeled cells adjacent to or within necrotic areas were also excluded while counting the 
Ki-67 LI. The means and standard deviations of Ki-67 LI were determined for each group. 
 
4.2.8 Statistical analysis 
Statistical analyses were performed using Graph Pad Prism 6 (GraphPad Prism 6 Software, San 
Diego, CA, USA). All p values <0.05 were considered statistically significant. Tumor volumes, 





















)], normalized ADC, rCBF, Ki-67 LI, and immunoexpression of PDGFRα, SULF2, 
and decorin were reported as means ± standard deviations. For statistical analysis, Student t-tests 
(independent-samples, two-tailed t-test) were used to assess the differences between means of the 
normal, untreated, and OKN-007 treated pediatric IC-3752GBM glioma mice. Kaplan-Meier 
survival curves and a Log-rank (mantel-cox) test were used to compare the survival times among 





Macroscopic, histological, immunohistochemical and MRI characteristics of the novel orthotopic 
xenograft pediatric glioblastoma (pGBM) model IC-3752GBM and the effects of OKN-007 to 
inhibit IC-3752GBM tumor cell growth were described in this report. 
Gross and microscopic characteristics of the IC-3752GBM pGBM model are presented in Figure 
4.1A–E. Macroscopically the tumors were characterized as a yellowish gray, poorly demarcated 
mass, with multifocal areas of necrosis and hemorrhage. Histological examination revealed 
highly cellular poorly demarcated, unencapsulated infiltrating neoplasm with marked cell atypia, 




Figure 4.1. Gross and microscopic lesions of the IC3752 pediatric glioma tumor. (A-B) 
Formalin fixed IC3752 pGBM tissue, characterized as a yellowish gray and poorly demarcated 
mass, with multifocal areas of necrosis and hemorrhage. (C-E) Histological examination revealed 
highly cellular, poorly demarcated, unencapsulated, and invasive neoplasms (E) characterized by 
marked cell atypia, a numerous mitotic figures (black arrows) (C), and multifocal areas of 
necrosis (asterisks) and hemorrhage (plus sign) (D). T = Tumor, B = normal brain. Scale bar=200 
μm (C-D). Scale bar=400 μm (E). 
To calculate the whole tumor volume in some animals, MSME T1-weighted images were 
performed and acquired before (Fig. 4.2A) and 15 min after (Fig. 4.2B) intravenous contrast agent 
injection (Gd-DTPA, Magnevist, Bayer Inc., Wayne, NY, USA). Figure 4.3D shows the 
quantitative mean IC-3752GBM tumor volumes calculated from MR images. Five animals were 
found to respond to OKN-007 treatment [OKN-007-(R)] and demonstrated significantly smaller 
tumors (p = 0.0430) (Fig. 4.3B) when compared with untreated animals (n=11) (Fig. 4.3A). It was 
also found that five pGBM mice did not respond [OKN-007-(NR)] to the OKN-007 therapy, and 
did not show statistical difference (p = 0.7244) when compared to the untreated group. 
 
 
Figure 4.2. Morphological images before and after contrast agent (Gd-DTPA) injection in a 
pGBM mouse model. (A) T1-weighted MR image. Before contrast administration the tumor 
appeared as a mildly hyperintense mass without clear demarcation (B) T1-weighted MR image. 
Fifteen minutes after the contrast injection the IC3752 pGBM demonstrates enhancement, 




Animal survival was assessed by comparing OKN-007–treated animals with untreated animals 
(Fig. 4.3C). It was found that six animals responded to the OKN-007 treatment and demonstrated 
significantly longer survival times (p = 0.0179) when compared with untreated animals (n=8). 
Conversely, five pGBM mice did not respond to the OKN-007 therapy, and showed no statistical 
difference (p = 0.4212) when compared to the untreated group. 
1
H-MRS values were obtained in normal athymic nude mice (n = 7), and untreated (n = 6) and 
OKN-007–treated (n = 8) mice bearing IC-3752GBM gliomas. Figure 4.4 shows the regions 




H-MR spectroscopy was placed in the brains of normal mice 
(Fig 4.4A) and mice bearing IC-3752GBM gliomas (Fig 4.4B). Figure 4.4C shows that the 









































 (p = 
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ratios of the normal mouse brain compared to the OKN-007-(R) group. 
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Figure 4.3. Effect of OKN-007 on tumor volumes and survival for IC3752 pGBM tumor 
bearing mice. Representative T2-weighted MR images of UT (A) and OKN-007 (B) treated IC 
3752 pGBM-bearing mouse brains. (C) Six animals responded to the OKN-007 treatment and 
demonstrated significantly longer survival times (p = 0.0179) when compared with UT animals 
(n=8). Five pGBM mice did not respond to the OKN-007 therapy, and showed no statistical 
difference (p = 0.4212) between the UT and OKN-007 (NR) groups. (D) Five animals responded 
to the OKN-007 treatment [OKN-007 (R)] and demonstrated significantly smaller tumors (p = 
0.0430) when compared with UT animals (n=11). However, five pGBM mice did not respond 
[OKN-007 (NR)] to the OKN-007 therapy, and there was no statistical difference (p = 0.7244) 
between the UT and OKN-007 (NR) group. Values are represented as means ± SD. Asterisks 





Figure 4.4. Brain metabolite ratios in normal and untreated vs. OKN-007 treated IC3752 
pGBM tumor bearing mice. Representative locations of the 2 x 2x 2 mm
3
 voxels used to 
perform 1H-MRS in normal mouse brain (A) and IC3752 pGBM tumor bearing mice (B). (C) 
The untreated IC3752 pGBM mice demonstrated a significantly lower NAAt/Chot ratio (p = 
0.0001) and higher Chot/Cren (p = 0.0325), Chot/NAAt (p = 0.0075), Lip0.9t/Cren (p = 0.0363) 
and Lip1.3t/Cren (p = 0.0009) ratios when compared to the normal athymic mouse brains. The 
Lip1.3t/Cren (p = 0.0395), Lip0.9 t/Cren (p = 0.0257), Chot/NAAt (p = 0.0167), and Chot/Cren 
(p = 0.0254) ratios were significantly lower in the OKN-007-(R) group when compared to 
untreated pGBM at the end phase of tumor progression. The OKN-007-(R) group showed a 
significantly higher NAAt/Chot (p = 0.0492) ratio than the untreated pGBM. There was no 
significant difference between the Chot/Cren (p = 0.498), NAAt/Chot (p = 0.6912), Chot/NAAt 
(p = 0.4231), and Lip0.9t/Cren (p = 0.6205) ratios for the normal mouse brains compared to the 
OKN-007-(R) group. The OKN-007-(R) group showed a significantly higher Lip1.3t/Cren (p = 
0.0047) ratio than the normal mouse brain. There was no significant difference between the 
NAAt/Chot (p = 0.2071), Chot/Cren (p = 0.7101), Chot/NAAt (p = 0.5362), Lip0.9t/Cren (p = 




In our study, with the use of DWI, the untreated group showed significantly higher (p = 0.0060) 
(1.161 ± 0.04538, n=11) normalized ADC values in the tumor regions when compared to the 
normal mice brains (1.003 ± 0.009358, n=6) (Fig. 4.5A-G). The OKN-007–R treated group had 
significantly higher normalized ADC values (1.296 ± 0.04141, n=7) compared to the untreated 
group (p = 0.0432) or the normal mice brains (p = 0.0003). All OKN-007 treated animals were 
found to be responsive to the anticancer therapy based on the ADC ratios when compared to the 
untreated group (Fig. 4.5G).  
When using perfusion imaging, the untreated group showed significantly higher (p < 0.0001) 
(0.1372 ± 0.04581, n=9) rCBF values for the tumor regions when compared to the normal mice 
brains (1.036 ± 0.03305, n=9) (Fig. 4.6A-G). The OKN-007–R treated group had significantly 
higher rCBF values (0.3624 ± 0.06599, n=4) compared to the untreated group (p = 0.0307) or the 
normal mice brains (p = 0.0004). There was no significant difference between rCBF values in the 
contralateral regions of OKN-007-R [104.8 ± 30.16 mL/(100g x min), n=4] and OKN-007-NR 
[111.9 ± 34.15 mL/(100g x min), n=2] or untreated [99.17 ± 19.50 mL/(100g x min), n=7] 
animals (Fig. 4.6G). 
Tumor cell proliferation was evaluated via immunoexpression of the anti-Ki-67 antibody. The Ki-
67 LI was significantly lower (p = 0.0181) in the OKN-007–R treated group (64.15 ± 0.5322, 
n=4) than in the untreated group (69.93 ± 1.524, n=6) (Fig. 4.7A–C). There was no significant 
difference (p = 0.1822) between the Ki-67 LI of the OKN-007–NR (78.33 ± 4.287, n=2) and 
untreated group. 
Microvessel density (MVD) were measured via the immunoexpression of the anti-CD31 
antibody. The MVD was significantly lower (p = 0.0358) in the OKN-007–R treated group (12.13 
± 1.648, n=3) than in the untreated group (20.41 ± 2.737, n=7) (Fig. 4.8A–C). There was no 
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significant difference (p = 0.3092) between the MVD of the OKN-007–NR (22.55 ± 3.014, n=4) 
and untreated group.   
 
Figure 4.5. Effect of OKN-007 on diffusion measured as ADC values in IC3752 pGBM 
tumor bearing mice. T2-images (top) and diffusion maps (bottom) of normal mouse brain (A-
B), untreated IC3752 pGBM (C-D), and OKN-007-R treated animal (E-F). (G) The untreated 
group had significantly higher (p = 0.0060) (1.161 ± 0.04538, n=11) normalized ADC values for 
the tumor region when compared to the normal mice brains (1.003 ± 0.009358, n=6). The OKN-
007–R treated group showed significantly higher normalized ADC values (1.296 ± 0.04141, n=7) 
compared to the untreated group (p = 0.0432) and normal mice brains (p = 0.0003). Values are 




Figure 4.6. Effect of OKN-007 on perfusion rates measured as rCBF in IC3752 pGBM 
tumor bearing mice. T2-images (top) and perfusion maps (bottom) of normal mouse brain (A-
B), untreated IC3752 pGBM (C-D), and OKN-007-R treated animal (E-F). (G) The untreated 
group showed significantly higher (p < 0.0001) (0.1372 ± 0.04581, n=9) rCBF values for the 
tumor regions when compared to the normal mice brains (1.036 ± 0.03305, n=9). The OKN-007–
R treated group showed significantly higher rCBF values (0.3624 ± 0.06599, n=4) compared to 
the untreated group (p = 0.0307) or normal mice brains (p = 0.0004). Values are represented as 





Figure 4.7. Effect of OKN-007 on cell proliferation in IC3752 pGBM tumor bearing mice. 
Immunohistochemistry images of Ki-67 levels in untreated (A) and OKN-007-treated (B) IC3752 
pGBM tumors. (C) Ki-67 LI was significantly lower (p = 0.0181) in the OKN-007–R treated 
group (64.15 ± 0.5322, n=4) than in the untreated group (69.93 ± 1.524, n=6). There was no 
significant difference (p = 0.1822) between the Ki-67 LI of the OKN-007–NR (78.33 ± 4.287, 
n=2) and the untreated groups. Values are represented as means ± SD. Asterisks indicate 







Figure 4.8. Effect of OKN-007 on microvessel density in IC3752 pGBM tumor bearing mice. 
Microvessel density (MVD) was measured via the immuno-expression of CD31. 
Immunohistochemistry images of CD31 levels in untreated (A) and OKN-007-treated (B) IC3752 
pGBM tumors. (C) The MVD was significantly lower (p = 0.0358) in the OKN-007–R treated 
group (12.13 ± 1.648, n=3) than in the untreated group (20.41 ± 2.737, n=7). There was no 
significant difference (p = 0.3092) between the MVD for the OKN-007–NR (22.55 ± 3.014, n=4) 
and the untreated groups. The MVA was significantly lower (p = 0.0009) in the OKN-007–R 
treated group (60.26 ± 5.179, n=3) than in the untreated group (127.7 ± 13.27, n=9). There was no 
significant difference (p = 0.5090) between the MVA of the OKN-007–NR (147.0 ± 22.75, n=3) 
and the untreated groups. Values are represented as means ± SD. Asterisks indicate statistically 





OKN-007 significantly decreased the immunoexpression of PDGFR-α in the treated responsive 
group (p = 0.0429) (28.58 ± 4.743, n=4) when compared to the untreated animals (43.82 ± 3.779, 
n=6). There was no significant difference (p = 0.1400) between the immunoexpression of 
PDGFR-α of the OKN-007–NR (53.17 ± 3.905, n=3) and the untreated groups (Fig. 4.9). 
OKN-007 also significantly decreased the immunoexpression of SULF2 in the treated responsive 
group (p = 0.0339) (23.99% ± 5.187, n=4) when compared to the untreated animals (53.17% ± 
7.389, n=3). There was no significant difference (p = 0.4180) between the immunoexpression of 
SULF2 of the OKN-007–NR (45.66% ± 1.686, n=2) and the untreated groups (Fig. 4.10). 
The immunoexpression of decorin was significantly higher (p = 0.0478) in the OKN-007–R 
treated group (22.86 ± 0.1479, n=2) compared to the untreated animals (11.73 ± 3.438, n=4). 
There was no significant difference (p = 0.0167) between the immunoexpression of decorin for 








Figure 4.9. Effect of OKN-007 on the immunoexpression of PDGFR-α in IC3752 pGBM 
tumor bearing mice. (Ai-Ci) Immunoexpression of PDGFR-α in normal mouse brain, IC3752 
pGBM UT, and OKN-007 treated animals, respectively. (Aii-Cii) Markup images for the 
immunoexpression of PDGFR-α in normal mouse brain, IC3752 pGBM UT, and OKN-007 
treated animals, respectively. (D) OKN-007 significantly decreased the immunoexpression of 
PDGFR-α (%) in the treated responsive group (p = 0.0429) (28.58 ± 4.743, n=4) when compared 
to the untreated animals (43.82 ± 3.779, n=6). There was no significant difference (p = 0.1400) 
between the immunoexpression of PDGFR-α of the OKN-007–NR (53.17 ± 3.905, n=3) and the 
untreated groups. Values are represented as means ± SD. Asterisks indicate statistically 
significant difference (*p < 0.05). n.s.: not statistically significant. Red = positive, blue = 




Figure 4.10. Effect of OKN-007 on the immunoexpression of SULF2 in IC3752 pGBM 
tumor bearing mice. (Ai-Ci) Immunoexpression of SULF2 in normal mouse brain, IC3752 
pGBM UT, and OKN-007 treated animals, respectively. (Aii-Cii) Markup images for the 
immunoexpression of SULF2 in normal mouse brain, IC3752 pGBM UT, and OKN-007 treated 
animals, respectively. (D) OKN-007 significantly decreased the immunoexpression of SULF2 
(%) in the treated responsive group (p = 0.0339) (23.99% ± 5.187, n=4) when compared to the 
untreated animals (53.17% ± 7.389, n=3). There was no significant difference (p = 0.4180) 
between the immunoexpression of SULF2 of the OKN-007–NR (45.66% ± 1.686, n=2) and the 
untreated groups. Values are represented as means ± SD. Asterisks indicate statistically 
significant difference (*p < 0.05). n.s.: not statistically significant. Red = positive, blue = 




Figure 4.11. Effect of OKN-007 on the immunoexpression of decorin in IC3752 pGBM 
tumor bearing mice. (Ai-Ci) Immunoexpression of decorin in normal mouse brain, IC3752 
pGBM UT, and OKN-007 treated animals, respectively. (Aii-Cii) Markup images for the 
immunoexpression of decorin in normal mouse brain, IC3752 pGBM UT, and OKN-007 treated 
animals, respectively. (D) The immunoexpression of decorin was significantly higher (p = 
0.0478) in the OKN-007–R treated group (22.86 ± 0.1479, n=2) compared to the untreated 
animals (11.73 ± 3.438, n=4). There was no significant difference (p = 0.0167) between the 
immunoexpression of decorin for the OKN-007–NR (18.44 ± 1.128, n=5) and the untreated 
groups. Values are represented as means ± SD. Asterisks indicate statistically significant 
difference (*p < 0.05). n.s.: not statistically significant. Red = positive, blue = background 




Animal modeling for primary brain tumors has undergone constant development over the last 60 
years, and significant improvements have been made recently with the establishment of highly 
invasive glioblastoma models through the direct implantation of patient tumors [10, 46]. 
However, animal models for pediatric HGGs are still an underexploited tool to make rapid 
advances in human cancer prevention, diagnosis, and therapy. 
This is the first description of the macroscopic, histological, immunohistochemistry and MRI 
characterizations of the novel orthotopic xenograft pediatric glioblastoma (pGBM) model IC-
3752GBM [45], and assessement of  the ability of OKN-007 to inhibit IC-3752GBM tumor cell 
growth. Previous reports are limited to the 
1
H-MRS characterization of medulloblastomas in 
transgenic mice [14] and in vitro 
1
H-MRS in other pGBM cell lines [15]. 
The anti-cancer response to OKN-007 in adult glioma models was previously reported by our 
group based on morphological (T2-weighted) imaging, bioluminescence imaging, and 
immunohistochemistry assessments, in addition to survival data [12, 22-23]. OKN-007 was found 
to significantly decrease tumor volumes (p < 0.05), as measured by MRI, and increase survival (p 
< 0.001) in F98 glioma-bearing rats [23]. Assessment of the treatment response using other MR 
parameters, such as 
1
H-MRS, DWI, and perfusion rates, was also performed by our group in C6 
rat gliomas [11, 22], but the use of a multi-parametric approach has not been previously reported 
for any pediatric glioblastoma model.  
From gross examination of the IC-3752GBM pGBM (Fig. 4.1A–B), the tumors were 
characterized as a yellowish gray, poorly demarcated mass, with multifocal areas of necrosis. 
Histological examination (Fig. 4.1C-E) revealed poorly demarcated, unencapsulated infiltrating 
neoplasms with marked cell atypia, a high mitotic index, and multifocal areas of necrosis and 
hemorrhaging, which is comparable to features for GBM in pediatric patients [2]. 
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From contrast-enhanced in vivo morphological MR imaging (Fig. 4.2B), IC-3752GBM pGBM 
tumors were characterized as mildly to markedly hyperintense, with poorly defined margins, and 
peripheral infiltration , sharing similar MRI characteristics with human glioblastomas [49]. 
Morphological MR images were also used to determine the volumes of individual tumors, starting 
on day 25 after the cell implantation, and continuing throughout the entire experiment. For the 
entire study, the therapeutic responses to OKN-007 were evaluated as either responsive (OKN-
007-R) or unresponsive (OKN-007-NR). One cohort of mice (n=5) were found to respond to 
OKN-007 treatment [OKN-007-(R)] and demonstrated significantly smaller tumors (p = 0.0430) 
when compared with untreated animals (n=11) (Fig. 4.3D). However, there were also non-
responsive mice [OKN-007-(NR)] (n=5) that seemed to be not affected to the OKN-007 therapy. 
For the responsive mice, our results were similar to prior adult glioma studies of our group, which 
showed that OKN-007 had a dramatic effect on regressing tumor formation in rat F98 [23] and 
C6 [12, 22], and human U87 xenograft [23] glioma models. 
The survival time of IC-3752GBM pGBM mice was also significantly increased in the responsive 
group after OKN-007 therapy, as we also have previously reported in adult glioma models [22-
23]. The OKN-007-R group (n = 6) had a median survival of 25.5 days, which was significantly 
longer (p = 0.0179) than the median survival of 18 days for the untreated group (n = 8) (Fig. 
4.3C). In our study, OKN-007 was able to increase the survival time by 7.5 days in the responsive 
group compared to the untreated animals. Considering that one mouse month is equivalent to 
∼2.6 human years, based on a 4-year maximum life span [50-51], OKN-007 could potentially 
increase survival time in pediatric GBM patients by ~7-8 months. 
We also assessed the OKN-007 treatment response by using other MR parameters, such as 
1
H-
MRS to measure tumor metabolites, DWI to assess structural alterations, and perfusion rates to 
evaluate microvascularity alterations. 
1
H-MRS is a non-invasive technique that measures the 
concentration of a variety of biomolecules from a volume of interest [52].  
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MRS findings have been shown to be closely related to the histological features of glioma cells 
and can be used for evaluating tumor differentiation, grading, follow-up and radiotherapy 
planning [53-55]. MRS is also a valuable tool for identifying early changes in glioma metabolism 
and the extent of glioma infiltration [56-58]. The technique is widely available clinically and 
easily appended to a standard MRI examination, which is routinely performed at the time of 
diagnosis on children with brain tumors [59]. The principal metabolites that can be assessed by 
1
H-MRS in brain tumors include choline (Cho, 3.2 ppm), creatine (Cre, 3.0 ppm), N-
acetylaspartate (NAA, 2.0 ppm), and lipids (Lip; 0.9–1.3 ppm) [58].  
Choline is a constituent molecule associated with the phospholipid metabolism of cell membranes 
and reflects membrane turnover [61]. Its concentration is slightly greater in white matter than in 
gray matter [61]. Increased Cho indicates greater membrane synthesis and cell proliferation [61]. 
Its concentration is markedly increased in cases of brain neoplasms [61]. Phosphocholine and 
glycerophosphocholine also contribute to the representation of the Cho peak in 
1
H-MRS [61].  
Creatine is a marker of aerobic energy metabolism in brain cells, and is present in larger 
concentrations in the gray matter than in the white [61]. Creatine and phosphocreatine, both of 
which contribute to the Cre pool, are found in both neurons and glial cells [61]. Cre and 
phosphocreatine remain relatively stable in vivo, and therefore their peak is often used as an 
internal concentration standard [62]. However, recent studies have suggested that the Cre levels 
may be altered in human gliomas [63].  
N-acetyl aspartate, a free amino acid, is almost exclusively located in neurons and axons, and is 
the most prominent signal observed in 
1
H-MRS for the CNS. The NAA peak in 
1
H-MRS is 
decreased whenever there is neuron loss, such as in gliomas, ischemia and degenerative diseases 
[61]. A strong association between 
1
H-MRS detectable lipids and tumor grade has been reported 
in adult gliomas [64-66] and childhood brain tumors [67] suggesting that high intracellular lipid 
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levels are a non-invasive marker of brain tumor malignancy. Studies on cultured cells, ex-
vivo tumor tissue and animal models have shown that an increase in MRS detectable lipids is 
associated with cell stress [68], apoptosis [69] and hypoxia as a result of compromised vascularity 
[70]. MRS detectable lipids are therefore associated with several factors known to be present in 
aggressive tumors that have a poor prognosis. 
In our study, we measured the peak areas of Cho, Cre, NAA, Lip0.9, and Lip1.3 in the normal 
brain of athymic nude mice and untreated and OKN-007 treated IC-3752GBM pGBM bearing 














































 (p = 0.0009) ratios when compared to the normal athymic mouse 
brain (Fig. 4.4C), which corroborates with metabolite profiles observed in human GBM. Typical 
1
H-MRS findings for cerebral gliomas includes reduction of NAA, variable levels of Cr, and an 
elevation in Cho and lipids, in proportion to glioma grade [71]. 
The role of mobile lipids in cancer has been the subject of many excellent reviews and articles 
[11-12, 70, 72-79]. In brain tumors, the elevation of lipid levels usually correlates with necrosis 
[72, 74, 80-81], and are considered as important biomarkers for diagnosis and monitoring the 
effects of treatment response [72]. A number of studies have also demonstrated that an increase in 
mobile lipids is associated with the onset of drug-induced apoptosis [68, 72]. OKN-007 
significantly reduced the lipid peaks at 1.3ppm (p = 0.0395) and 0.9 ppm (p = 0.0257)
 
in treated 
animals compared to the untreated group, which could be related to a decrease in tumor necrosis 
by OKN-007 in treated animals. This anticancer property of OKN-007 may be very beneficial for 
GBM patients, since necrosis is caused by tumor hypoxia as a result of increased cell proliferation 
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and mitotic activity, as well as insufficient tissue perfusion [82], and it is present in over 85% of 
cases [83-86].  





ratio (p = 0.0167) than the untreated group. The effect of OKN-007 on the Cho/NAA 
ratio in the IC-3752GBM pGBM model is remarkable, since it has been reported that the 
Cho/NAA ratio provides a sensitive method for detecting differences in tumor growth [87]. 
Furthermore, baseline Cho/NAA ratios and the percent change in Cho/NAA over time have also 
been associated with poor prognosis in childhood brain tumors [88-90]. Lower Cho/NAA ratios 
seem to be predictive of a poor outcome in children with recurrent primary brain tumors, and 





ratios also significantly decreased (p = 0.0254) after OKN-007 treatment in 
responsive animals compared to untreated pGBM at the end phase of tumor progression (Fig 
4.4C), indicating that the drug was also capable of decreasing tumor cell proliferation in ~50% of 
animals in this pediatric glioma model. The 
1
H-MRS results were also confirmed with IHC that 
showed significantly lower (p = 0.0181) immunoexpression of Ki-67 (cell proliferation marker) 
in the OKN-007–R treated group compared to untreated animals (Fig. 4.7C). 
Diffusion-weighted imaging (DWI) represents another promising imaging tool for tissue 
characterization, prediction, and the evaluation of therapeutic response in oncology [91]. DWI is 
routinely used to measure microscopic, random translational motion of water molecules within 
tissues. Any alterations in the tissue structure that disrupt the barriers of water diffusion, such as 
the breakdown of cell membranes or damage to fibers, would lead to changes in the diffusion 
properties within these regions. These diffusion characteristics can be quantified by estimating 
the ADC (Apparent Diffusion Coefficient). In tumors, ADC values can differentiate the cellular 
mechanisms involved in tumor development as well as responses to treatment such as cell 
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proliferation, apoptosis, and/or necrosis [92]. Both intra- and extracellular spaces and their 
exchange contribute to the measured ADC [93]. DWI has also a tremendous potential for 
monitoring early changes in tumor cellularity that are thought to be reflective of treatment 
response [93]. As cellular density increases, the added tortuosity to extracellular mobility paths 
reduces water mobility and, consequently, the ADC value [94]. Processes that degrade cellular 
integrity, such as necrosis caused by therapy or tumor growth, are thought to increase the ADC of 
tissue [94-95]. Successful treatment of a tumor with a cytotoxic agent will result in significant 
damage to the tumor cells in the form of a loss of cell membrane integrity with a subsequent 
reduction in tumor cell density. This has a net effect of increasing the fractional volume of the 
interstitial space because of cell loss, resulting in an increase in the mobility (diffusion) of water 
within the damaged tumor tissue [93]. 
In our study, the untreated group showed significantly higher (p = 0.0060) (1.161 ± 0.04538, 
n=11) normalized ADC values for the tumor region when compared to the normal mice brain 
(1.003 ± 0.009358, n=6) (Fig. 4.5G). The OKN-007–R treated group showed significantly higher 
normalized ADC values (1.296 ± 0.04141, n=7) than the untreated group (p = 0.0432) and normal 
mice brains (p = 0.0003). Interestingly, all OKN-007 treated animals were responsive to the 
therapy based on the ADC ratios when compared to the untreated group. The observed increase in 
water ADC following therapy is directly related to the number of tumor cells killed and is thought 
to be due to the liberation of water into the extracellular space [94]. 
Arterial spin labeling (ASL) is a non-invasive magnetic resonance technique for tissue perfusion 
quantification without the application of contrast media. Perfusion is defined as the amount of 
blood delivered to capillary beds in a given tissue per unit time.  Delivery of blood to a capillary 
bed is a critical indicator of tissue viability and function, and the analysis of perfusion [96], which 
has markedly contributed to the understanding of physiological and pathological processes in the 
human body [97]. Furthermore, the ASL technique has been useful for monitoring the effects of 
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agents designed to modulate tumor blood flow and oxygenation (e.g., carbogen gas) [98], and for 
evaluating and guiding the use of anti-angiogenic agents [44]. 
Antiangiogenic therapy might affect tumor vessels in 3 different ways: no effect at all; excessive 
destruction of blood vessels and a reduction in perfusion leading to increased hypoxia, necrosis, 
and/or invasion; or after pruning of some abnormal vessels the overall structure of the remaining 
tumor vessels may resemble normal vessels, which potentially results in an increase in absolute 
blood perfusion [99]. In this study, we measured the changes in normalized relative cerebral 
blood perfusion (rCBF) in normal athymic mouse brains, and in untreated and OKN-007 treated 
IC-3752GBM pGBM mice, using the ASL perfusion MRI technique. The untreated group 
showed significantly lower (p < 0.0001) (0.1372 ± 0.04581, n=9) rCBF values for the tumor 
region when compared to the normal mice brain (1.036 ± 0.03305, n=9) (Fig. 4.6G). The OKN-
007–R treated group showed significantly higher rCBF values (0.3624 ± 0.06599, n=4) compared 
to the untreated group (p = 0.0307) and significantly lower than normal mice brains (p = 0.0004). 
Interestingly, the drug did not seem to affect the normal perfusion of the brain, as no differences 
were found between values in the contralateral regions of OKN-007-R [104.8 ± 30.16 mL/(100g 
x min), n=4] and OKN-007-NR [111.9 ± 34.15 mL/(100g x min), n=2] and untreated [99.17 ± 
19.50 mL/(100g x min), n=7] animals (Fig. 4.6G), being consistent with the findings from 
previous research studies in OKN-007-treated C6 gliomas [22]. Our results also corroborate with 
the literature that indicates that glioblastomas have lower blood perfusion rates than that of the 
surrounding normal brain because of their inefficient, irregular vessels that are leaky and dilated 
with a haphazard pattern of interconnection [99-100].   
The positive effect of OKN-007 on perfusion and diffusion properties in IC-3752GBM pGBM 
bearing mice indicates a promising influence of the drug on tumor microvasculature, which was 
also shown previously in a rat adult glioma model by our group [22]. In our study, we were also 
able to demonstrate that OKN-007 acts as an antiangiogenic agent in the IC-3752GBM pGBM 
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model. To support this notion, microvessel density (MVD) was significantly lower (p = 0.0358) 
in the OKN-007–R treated group than in the untreated group (Fig. 4.8C). The normalization of 
tumor vasculature is a necessary step for cancer therapies [101]. This effect may be mediated by 
the anti-inflammatory properties of OKN-007. Indeed, alterations to inflammatory pathways can 
modify angiogenesis [102], and inflammatory mediators are known to modulate blood–brain 
barrier permeability [103]. Therefore it could be expected from the anti-inflammatory properties 
of nitrone compounds, that administration of OKN-007 positively altered the integrity and 
function of the microvascular bed at the tumor site, consequently increasing the ADC ratios and 
rCBF values in responsive treated animals.  
We also assessed the effect of OKN-007 regarding the immunoexpression of tumor signaling 
molecules such as PDGFRα, SULF2, and decorin in the IC-3752GBM pGBM model. Although 
childhood and adult HGGs share related histopathological characteristics, recent studies have 
shown substantial differences in the molecular features underlying pediatric and adult HGGs. The 
epidermal growth factor receptor is the predominant receptor tyrosine kinase targeted by both 
amplification and mutation in adult glioblastomas [104-105]. In contrast, PDGFRα is the most 
frequent target of focal amplification in pediatric HGGs arising within and outside the brainstem 
[106-110], and somatic mutations of PDGFRα have been recently reported in pediatric HGGs 
[108-109, 111]. Another study revealed that the high expression of phosphorylated PDGFRα has 
a significant association with malignant histology in pediatric gliomas [112]. The expression of 
PDGFRα has also been demonstrated in medulloblastomas and primitive neuroectodermal 
tumors, and an increase in PDGFRα gene copy numbers seems to be associated with poor 




SULF2, a heparan sulfate endosulfatase, has been associated to different types of cancers 
including lung [114], breast [115], liver [116], gastric [117], and brain tumors [118]. In brain 
cancer, SULF2 has been directly implicated in driving tumorigenesis in murine and human 
malignant gliomas [119]. The SULF2 protein is highly expressed in primary human GBM, and 
SULF2 levels are inversely related to heparan sulfate proteoglycan (HSPG) 6O-sulfation in a 
murine model for GBM [119]. SULF2 gene expression is also significantly positively correlated 
with PDGFRα expression [120]. Furthermore, the ablation of SULF2 decreases tumor growth, 
prolongs host survival and decreases the activity of PDGFRα, as well as related downstream 
signaling pathways in human and mouse malignant gliomas [119]. 
Decorin is a small proteoglycan found in the extracellular matrix of a variety of tissues and cell 
types [120-121]. It interacts with a diversity of proteins that are involved in matrix assembly 
[122] and in the regulation of fundamental biological functions such as cell attachment [123], 
migration [124], and proliferation [125]. Decorin inhibits cell proliferation in several tumor cell 
types, including ovarian [123], liver [126], and brain tumor cells [127]. Similarly to SULF2, 
decorin is also associated to the PDGFRα pathway. Interestingly, decorin does not colocalize with 
PDGFRα, but binds directly to its natural ligand PDGF, directly blocking the activity of PDGFRα 
[126]. Furthermore, it is known that decorin antagonizes the angiogenic network  [128] due to the 
inhibition of the production of VEGF (vascular endothelial growth factor) by tumor cells and can 
directly blocking of VEGFR2 (vascular endothelial growth factor receptor-2) at the same time 
[129]. 
Our current data showed that OKN-007 was able to significantly decrease the immunoexpression 
of SULF2 (p = 0.0339) in responsive mice compared to untreated animals, which has also been 
recently demonstrated in hepatocellular cancer cells [130]. Furthermore, OKN-007 was able to 
significantly decrease the immunoexpression of PDGFRα (p = 0.0429) and significantly increase 
the expression of decorin (p = 0.0478) in responsive IC-3752GBM pGBM tumor bearing mice, 
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compared to untreated animals, which may be also associated to the inhibition of tumor 
angiogenesis and cell proliferation which was also observed in the OKN-007-R treated animals 












Figure 4.12. Schematic representation of possible mechanism of action of OKN-007 in 
IC3752 pGBM tumor bearing mice. Heparan sulfate proteoglycans (HSPG) consist of a protein 
core and heparan sulfate (HS) chains consisting of linear carbohydrate chains of repeating 
disaccharide units. Dependent on the HSPG core protein, HSPGs are found at the cell surface (1), 
in the extracellular matrix (2), or in secretory vesicles [119]. Essential for their function in cell 
signaling, the HS chains undergo extensive post-translational modifications, including sulfation 
on the 6-O- position of glucosamine [131]. By removing 6-O-sulfates on HS chains and 
mobilizing protein ligands from HSPG sequestration in the extracellular environment (3), the 
SULF-2 can increase the solubility of a variety of growth factors (e.g. PDGF) (4) thus increasing 
the activation of PDGFR-α and downstream signaling pathways in tumor cells (5) [119]. 
Similarly to SULF2, decorin is also associated to the PDGFRα pathway. Interestingly, decorin 
does not co-localize with PDGFRα, but binds directly to its natural ligand PDGF, directly 
blocking the activity of PDGFRα (6) [126]. Our current data showed that OKN-007 was able to 
decrease the immunoexpression of SULF2 (7) and PDGFRα (8), and increase the expression of 
decorin (9) in IC3752 pGBM tumor bearing mice, which may be also associated to the inhibition 
of tumor angiogenesis and cell proliferation (10) also observed in OKN-007 treated animals. 
SO3-: sulfate, PDGF: Platelet-derived growth factor. The schematic is a modification of 
combined schemes obtained from Oncotarget, 3(5): 568–575, Phillips JJ (2012) [119] (Copyright 
(2012) with permission from Impact Journals), and from FEBS Journal, 280(10):2150-2164, 




The data taken as a whole indicates that OKN-007 may be an effective anti-cancer agent for some 
patients with pHGGs by inhibiting cell proliferation and angiogenesis, possibly via the PDGFRα 
pathway, and could be considered as an additional therapy for pediatric brain tumor patients. 
Currently, OKN-007 is an investigational drug in phase Ib/IIa clinical trials for recurrent adult 
GBM patients. Our future plan is to conduct clinical trials in pGBM patients using OKN-007 as 
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General conclusions  
 
The overall hypothesis (H0) of my PhD dissertation was to explore the anticancer properities in 
different glioma animal models. This principal hypothesis was evaluated in four different studies, 
which were based on the OKN-007 activity to decrease tumor necrosis, tumor cell proliferation, 
and free radical and VEGFR-2 levels in adult gliomas, as well as based on OKN-007 anticancer 
activity in a pediatric glioma mouse model (Fig 5.1). 
 
Overall hypothesis (H0): OKN-007 is an effective anti-glioma agent 
Adult glioma models 
H1: OKN-007 decreases tumor necrosis and cell proliferation in a F98 rat glioma 
model 
H2: OKN-007 decreases free radical levels in a F98 rat glioma model 
H3: OKN-007 decreases VEGFR-2 levels in a GL261 mouse glioma model  
Pediatric glioma model 
H4: OKN-007 has anticancer activity in a pediatric glioma mouse model 
 





These studies demonstrated that OKN-007 was able to increase the survival time, decrease tumor 
volume, tumor cell proliferation, tumor necrosis, and tumor angiogenesis in both adult and 
pediatric gliomas (Fig 5.2). OKN-007 also increased tumor cell apoptosis and decreased free 
radical levels in adult gliomas (Fig 5.2). Further studies to establish the target pathway of OKN-
007, which may be TGFβ1, will need to be conducted. Furthermore, OKN-007 decreased the 
immunoexpression of PDGFR-α and SULF-2, and increased the immunoexpression of decorin in 
pediatric gliomas (Fig 5.2). The PDGFR pathway may be a possible target for OKN-007 in 
pediatric gliomas, which will need to be further studied.  
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